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although expression patterns on SM cells will require antibodies that can detect SM proteins. This finding
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reveals that SIVsmm can infect target cells in vivo using non-CCR5 entry pathways. Since CD4/coreceptor
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GPR15. Combined with restricted expression of CCR5 on critical target cells previously described,
alternative coreceptor-dependent targeting may allow virus replication in more expendable cells without
loss of immune cell homeostasis. We hypothesize that SM natural hosts may have evolved to restrict
expression of CXCR6 and GPR15, in addition to CCR5, to dispensable cell subsets, thus allowing for high
viral replication without causing disease. Future studies comparing CXCR6 and GPR15 expression profiles
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ABSTRACT
A NOVEL CCR5 MUTATION IN SOOTY MANGABEYS REVEALS SIVSMM
INFECTION OF CCR5-NULL NATURAL HOSTS: EXAMINING THE POTENTIAL
ROLES OF ALTERNATIVE ENTRY PATHWAYS IN HIV AND SIV INFECTION
Nadeene E. Riddick
Ronald G. Collman, M.D.
Natural hosts of SIV, such as sooty mangabeys (SM), maintain high levels of virus
replication, but do not typically develop CD4+ T cell loss and immunodeficiency.
Understanding the virus/host relationship in natural hosts will enable better understanding
of pathogenic HIV infection of humans. Host cell targeting in vivo is an important
determinant of pathogenesis, and is defined mainly by expression of coreceptors used by
the virus for entry, in conjunction with CD4. Established dogma holds that, with rare
exceptions, SIV uses CCR5 for entry. However, SM and other natural hosts express
extremely low CCR5 levels on CD4+ T cells. I identified a novel SM-CCR5 mutant
allele containing a two base-pair deletion (CCR5∆2) that results in a non-functional
protein. Using PCR screening and direct sequence confirmation in a large captive SM
colony, I found an allelic frequency of 26% for CCR5∆2, along with 3% for a previouslydescribed CCR5∆24 null allele. Notably, SM-CCR5∆2 was also present in West African
wild-living SM. Approximately 8% of captive SM were homozygous for CCR5-null
alleles. Surprisingly, SIVsmm infection was not significantly less prevalent in SM
lacking functional CCR5 compared to CCR5-expressing animals, and CCR5-null animals
displayed high-level viremia. Primary PBMC from SM were permissive for SIVsmm
replication in both the absence and presence of CCR5 in vitro. Pseudotype virions
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carrying Envs from both CCR5-null and wild-type infected SM used CXCR6 and GPR15
efficiently for entry in transfected cells, suggesting likely alternative entry molecules. In
preliminary studies using human cells, I found that CD4+ T cell expression of CXCR6
and GPR15 was predominantly on central and effector memory subsets, although
expression patterns on SM cells will require antibodies that can detect SM proteins. This
finding challenges the long-standing notion that CCR5 is the exclusive coreceptor used
for SIV entry in vivo, and reveals that SIVsmm can infect target cells in vivo using nonCCR5 entry pathways. Since CD4/coreceptor interactions determine viral tropism and
cell targeting, these results suggest that infection in natural host SM may involve target
cells defined by the distribution and use of alternative coreceptors CXCR6 and GPR15.
Combined with restricted expression of CCR5 on critical target cells previously
described, alternative coreceptor-dependent targeting may allow virus replication in more
expendable cells without loss of immune cell homeostasis. We hypothesize that SM
natural hosts may have evolved to restrict expression of CXCR6 and GPR15, in addition
to CCR5, to dispensable cell subsets, thus allowing for high viral replication without
causing disease. Future studies comparing CXCR6 and GPR15 expression profiles in
natural and non-natural hosts will be of importance in determining the role of alternative
coreceptors in natural hosts in vivo.
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CHAPTER I

GENERAL INTRODUCTION

1

Epidemiology
In 1983, two laboratories identified human immunodeficiency virus (HIV) as the
virus that causes acquired immunodeficiency syndrome (AIDS) (7, 82). Over the past 30
years, HIV has become a leading cause of death worldwide especially in regions of subSaharan Africa (1). As of 2010, an estimated 34 million people are living with HIV
worldwide, which has increased 17% from the number of infected individuals in 2001.
This increase in HIV prevalence reflects new infections as well as an increase in the life
expectancy of HIV-infected individuals due to more effective therapeutics and a
significant rise in access to antiretroviral therapy (ART). Although there is an increase in
the total number of people living with HIV over the past decade, the estimated number of
new HIV cases (2.7 million) was 21% lower in 2010 than the number of new infections
in 1997, at the peak of the HIV epidemic (1). However, there is still no cure or vaccine
available against HIV, which is a major issue since a large proportion of people living
with or at risk for infection, in developing countries, still do not have access to treatment
or care.
HIV is transmitted through the transfer of bodily fluids (i.e. blood, semen, vaginal
fluid, and breast milk) from an infected individual to an uninfected recipient. The major
routes of HIV transmission are unprotected sex, contaminated needles, during birth
(perinatal), and through breast milk (25, 47, 92) Notably, the main route of transmission
differs from region to region. Historically, in the U.S., HIV infection predominantly
affected intravenous drug users and men who have sex with men (MSM). Although,
these groups remain at high risk for infection, heterosexual transmission accounts for a
growing number of HIV cases in the U.S., especially among women. The HIV epidemic
2

in Eastern Europe is primarily driven by intravenous drug users, while the HIV epidemic
in Sub-Saharan Africa and parts of the Caribbean are mainly the result of heterosexual
contact.

HIV disease pathogenesis
HIV infects CD4+ T lymphocytes and macrophages, which play critical roles in
both the innate and adaptive arms of the immune system. A typical HIV infection
consists of three stages: the acute (primary) infection, the chronic infection (clinical
latency), and the onset of AIDS. The acute phase generally lasts several weeks with
symptoms ranging from asymptomatic to flu-like in infected individuals. During this
stage, an inverse correlation between plasma viremia and peripheral blood CD4+ T cell
counts is observed, in which CD4+ T cell counts decrease concomitant with peak viremia
(24). Early in infection, memory CD4+ T lymphocytes are preferential targets of HIV,
likely due to their moderate to high CCR5 expression and activated state. The majority
of activated memory CD4+ T cells reside in the gut associated lymphoid tissue (GALT).
HIV infection leads to a rapid and massive depletion of these cells, which is sustained
throughout the course of infection (13, 89). Towards the end of the acute phase, viral
loads decline to a set level and peripheral blood CD4+ T cell counts partially rebound as
demonstrated in Figure 1-1.
The chronic phase of infection is characterized by a prolonged asymptomatic
period lasting for many years. Throughout this period of clinical latency, viral loads
gradually increase while CD4+ T cell counts slowly decline (35). Notably, infected
persons remain infectious during this period (59, 80). At the end stage of disease (AIDS),
3

CD4+ T cell counts in the blood are extremely low likely due to direct viral killing of
infected cells, an increased rate of apoptosis of infected and bystander (uninfected) cells,
and cell-mediated killing of infected cells (96). When CD4+ T cell counts decrease
below a critical threshold, cell-mediated immunity is severely compromised and the host
becomes more susceptible to opportunistic infections (72, 83).
The development and use of antiretroviral therapy (ART) has dramatically
reduced HIV-related mortality and morbidity in middle to high-income countries where
access to ART is available. In the late 1980’s, antiretroviral (ARV) drugs became
available for use by HIV-infected patients. However treatment with a single ARV drug
led to drug resistant strains of the virus given that HIV mutates at a high rate due to its
rapid and persistent replication combined with the lack of polymerase proofreading
activity (50, 51). In the mid 1990’s, combination therapy was developed, which defends
against HIV resistance by suppressing HIV replication at multiple stages in the virus life
cycle. Highly active antiretroviral therapy (HAART) consists of a combination of three
or more antiretroviral drugs that maximally suppress HIV replication. With proper use,
HAART suppresses HIV viral loads below detectable levels reducing the likelihood of
HIV transmission by infected individuals. However, inconsistent use of HAART can
lead to multi-drug resistant strains, which considerably limits future treatment options.
Unfortunately, access to drug treatments are not uniformly available in low and middleincome countries, where treatment needs are the greatest.
While the majority of HIV-infected persons ultimately progress to AIDS if left
untreated, a small percentage of HIV-infected individuals appear to naturally control the
infection, called long term non-progressors (LTNP). There is no universally accepted
4

definition for LTNP, but in general these infected individuals maintain a normal range of
CD4 T cell counts in the peripheral blood without the use of antiretroviral therapy, and do
not progress to AIDS after prolonged periods of observation. LTNP may have
detectable viral loads that typically do not exceed more than 2,000 copies/ml. A subset
of LTNP called elite controllers (EC) have undetectable viral loads (< 50 copies/ml) and
naturally maintain normal CD4 T cell counts in the blood, without the use of
antiretroviral therapy (28).
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Figure 1-1. Viral and cellular parameters of disease progression during HIV-1 infection.
Acute infection is characterized by a peak in viral load and a rapid increase in immune activation.
During this phase, mucosal CD4 T cells are severely depleted while a transient decrease in
peripheral blood (PB) CD4 T cells is observed, which partially rebounds towards the early stage
of chronic infection. During chronic infection, viral loads are maintained at a viral set point and
immune activation remains elevated while mucosal CD4 T cell counts remain low and CD4 T
cells in the periphery begin to steadily decline. When PB CD4 T cells decrease below a critical
threshold, this defines the onset of AIDS, which is characterized by an increase in viral
replication and severe immunodeficiency, resulting in opportunistic infections. Schematic was
adapted from Grossman, Z. et al. Nature Medicine 2006.
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SIV: origins of HIV-1 and HIV-2	
  
Through comparative sequence analysis, the origins of HIV have been traced to
specific strains of SIV found in African non-human primates (NHP). HIV-1 is the result
of cross-species transmission of a strain of simian immunodeficiency virus (SIV) found
in chimpanzees, SIVcpz (56, 58, 101). Hahn et al. determined that all examined HIV-1
isolates from groups M, N and O were only closely related to lineages of SIVcpz found in
the chimpanzee subspecies, Pan troglodyte troglodyte, inferring that on at least three
separate occasions, SIVcpz crossed into the human population (40). Chimpanzees were
originally categorized as a natural host of SIV, however recent studies revealed that SIVinfected chimpanzees exhibited increased mortality and morbidity compared to
uninfected animals, and they are now designated as intermediate hosts of SIV (60).
Studies indicate that SIVcpz contains a recombinant genome with regions similar to two
strains of SIV, SIVrcm found in red-capped mangabeys (RCM; Cercocebus torquatus)
and SIVgsn found in greater-spot nosed monkey (Cercopithecus nictitans) (5). HIV-2
and SIVmac are also the result of two separate cross-species transmission events of
SIVsmm, a strain of SIV found in sooty mangabeys (SM), into the human and rhesus
macaques (RM) populations, respectively (19, 20, 41, 42, 52). Currently, over 40
different species-specific SIV strains have been identified in African NHP, thus the
possibility of another zoonosis into the human population is plausible. The phylogenetic
relationship between SIVcpz/HIV-1 and SIVsmm/HIV-2 is depicted in Figure 1-2.
SIV is endemic in African NHP and infected natural hosts live a normal lifespan
and remain asymptomatic, despite high viral loads (95). In stark contrast, SIV-infected
non-natural hosts (i.e. Asian macaques) experience an AIDS-like disease that results in
7

death due to opportunistic infections. The pathogenic potential of SIV was first observed
when lymphoma outbreaks occurred in captive Asian macaques (RM and stump-tailed
macaques), which had been in contact with SIV-infected SM prior to the outbreaks.
Inadvertently, this virus was serially transmitted to other macaques giving rise to the
well-established SIVmac strain (27). SIV-infected RM exhibit a disease course similar to
that of HIV-infected humans, therefore SIV-infected RM serve as a valuable animal
model to study HIV infection.

8

Figure 1-2. Phylogenetic relationship among HIV and SIV strains. This phylogenetic tree
was generated based on the similarity of pol gene sequences between various strains of HIV and
SIV. This tree clearly demonstrates that HIV-1 (groups M, N and O) is closely related to SIVcpz
pol sequences while HIV-2 is most closely related to SIVsmm. Notably, HIV-1 N group and
SIVagmSAB have recombined genomes. Based on pol gene relatedness, the HIV-1 N group is
more closely related to the HIV-1 M group, as shown. However, based on env gene phylogenies,
the HIV-1 N group clusters within the SIVcpz (P.t.t) clade. SIVagmSAB is recombinant with other
SIVagm strains and SIVsmm. Due to a recombination event in the pol gene of SIVagmSAB, this
branch is placed between SIVagm and SIVsmm, however the placement of SIVagmSAB branch
does not reflect true evolutionary history. Small arrows indicate the branch position of
recombinant viruses (HIV-1 N group and SIVagmSAB) based on an env phylogenetic tree
reconstruction. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory,
1999.
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Chronic Immune Activation
Chronic immune activation is a key feature that distinguishes non-pathogenic
from pathogenic infection. Typical features of HIV-associated chronic immune
activation include a higher frequency of activated T and B cells, increased lymphocyte
turnover, high activation-induced cell death and high levels of pro-inflammatory
cytokines and chemokines in serum from infected individuals. Interestingly, the acute
phase of SIV infection in natural and non-natural hosts is characterized by strong innate
and adaptive immune responses to the virus. However, natural hosts downregulate this
response early in the chronic phase and maintain a low immune activation state
throughout infection.
Both viral and host factors appear to contribute to chronic immune activation.
The role of virus-induced immune activation is demonstrated by the fact that ART
reduces immune activation in HIV-infected persons (32). However, viral factors alone
cannot account for HIV/SIV-associated immune activation since SIV-infected natural
hosts exhibit high levels of viral loads while immune activation during the chronic phase
of infection is relatively low (15, 96). Viral factors associated with immune activation
likely include HIV/SIV-induced innate and adaptive immune responses and re-activation
of latent viruses, while host factors associated with immune activation may include
mucosal immune dysfunction and homeostatic proliferation.
Numerous HIV/SIV-specific viral factors may contribute to chronic immune
activation including: (i) gp120-mediated signaling through CD4 and/or coreceptor, (ii)
specific antiviral adaptive immune responses elicited by HIV/SIV-specific T and B cells
(68), and (iii) stimulation of the innate immune response via pattern recognition receptors
10

(toll-like receptors) that recognize components of bacterial pathogens (which may have
entered the bloodstream as a result of microbial translocation) and HIV-derived ligands
(HIV single-stranded RNA) (4, 12). Additionally, during the late stage of disease,
reactivation of latent viruses may contribute to chronic immune activation. This can
occur in the setting of a compromised immune system where latent herpes viruses (i.e.
cytomegalovirus [CMV] and Epstein-Barr virus [EBV]) frequently reactivate, which may
stimulate large numbers of T cells specific for CMV and/or EBV viral antigen (73).
During early stages of infection, studies suggest that damage to the
gastrointestinal (GI) immune system may increase systemic immune activation during the
chronic phase of pathogenic HIV/SIV infection. During acute infection, mucosal CD4 T
cells are severely depleted, likely since a large proportion of these cells express the HIV
co-receptor, CCR5 (45, 79). Mucosal CD4 T cells are primarily comprised of Th1 and
Th17 cells, which produce and secrete interferon-gamma (IFN-g) and interleukin-17 (IL17), respectively. Profound depletion of Th17 cells is associated with a breakdown in the
mucosal barrier resulting in translocation of microbial products (i.e. LPS and flagellin)
from the intestinal lumen to systemic circulation (12, 33). Aberrant circulation of
microbial products may cause broad immune activation through TLR-mediated
stimulation of immune cells as well as triggering bystander activation of circulating
lymphocytes. Evidence demonstrating a causal relationship between microbial
translocation and immune activation is seen in SIV-infected natural hosts where lack of
microbial translocation in these animals is associated with attenuated chronic immune
activation (6, 12, 16, 97).
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Another factor that potentially affects chronic immune activation is homeostatic
proliferation. Homeostatic proliferation is the ability of T cells to divide in the absence
of activation, and is aimed at repopulating particular T cell pools. During acute HIV
infection, there is severe and persistent depletion of mucosal CD4 T cells in the gut as
well as transient depletion of CD4 T cells in the blood. The adaptive immune system
responds by proliferation of HIV/SIV-specific T cells in response to encountering viral
antigen, however antigen-independent homeostatic proliferation also occurs in an attempt
to replenish the continuously depleting CD4 T cell pool. A clear relationship between
intestinal CD4 T cell depletion and systemic/intestinal CD4 T cell proliferation was
demonstrated in HIV-infected and uninfected individuals (44, 98).

Divergent host responses to SIV infection
As previously mentioned, SIV infection of natural hosts is non-pathogenic while
HIV/SIV infection of non-natural hosts results in a pathogenic infection, characterized by
chronic immune activation, immunodeficiency and ultimately death as a result of
opportunistic infections. However, the mechanisms underlying the absence of disease in
infected natural hosts are poorly understood. Schematics highlighting similarities and
differences in key parameters of pathogenic and non-pathogenic SIV/HIV infections are
depicted in Figure 1-3.
There are a number of key features that differ between SIV-infected natural and
non-natural hosts, however one shared feature is high levels of virus replication.
Originally, researchers hypothesized that absence of disease in infected natural hosts may
be due to non-pathogenic or less fit virus. However, subsequent studies indicated that
12

lack of disease progression in natural hosts is not associated with low levels of viral
replication (15, 53, 84, 96). Many studies have confirmed that infected natural hosts
exhibit viral loads equal to or greater than viral loads seen in SIV-infected non-natural
hosts (15, 84, 94).
While both non-pathogenic and pathogenic infections result in high viral loads,
pathogenic infections result in CD4+ T cell loss in the blood, and progression to AIDS,
which is extremely rare in infected natural hosts (14, 76). However, studies have
demonstrated rare instances in which SIV-infected SM experienced severe depletion of
peripheral blood CD4+ T cells, either naturally or experimentally, yet these animals did
not progress to AIDS (69, 70). This observation suggests that natural hosts have
developed at least two levels of protection in response to SIV infection: i) protection from
loss of CD4+ T cells during SIV infection (possibly due to mechanisms which maintain
homeostasis of the immune system), and ii) protection from AIDS when CD4+ T cells
are lost (69, 70).
As previously mentioned, a key feature that differs between infected natural and
non-natural hosts is chronic immune activation. Immune activation during the acute
phase of infection is exhibited in both pathogenic and non-pathogenic infections,
however studies indicate that infected natural hosts downregulate immune responses
through mechanisms not fully understood, during early chronic infection (10, 48, 57).
Differential downregulation of innate immune responses can be observed in SM and
African green monkeys (AGM) natural hosts, which downmodulate type I interferon
responses within four to six weeks post-infection, whereas SIV-infected RM exhibit
persistently high interferon responses throughout the chronic phase of infection (48).
13

This is only one such example where natural hosts have evolved mechanisms to attenuate
chronic immune activation.
Intriguingly, depletion of gut memory CD4+ T cells occurs in both SIV-infected
natural and non-natural hosts (45, 79), however microbial translocation is only observed
in pathogenic SIV infections. Microbial translocation, which likely results from a breach
in the gut epithelial barrier, is thought to be a major driver of chronic immune activation
(12, 33). Studies suggest that the sparing of CD4+ Th17 cells in the gut of infected
natural hosts may contribute to intact gut immunity and the absence of microbial
translocation in these hosts (11). Notably, an association between circulating microbial
products and immune activation was emphasized in a study where a single dose of LPS
was administered to chronically SIVagm-infected AGM, which led to an increase in
proliferation and activation of CD4+ T cells, as well as an increase in viral loads (78).
However, whether induced-immune activation in these animals would have progressed to
disease is unknown since this was a short-term study.
Another major difference between natural and non-natural hosts is the level of
CCR5 expression on CD4+ T cells. SIV natural hosts express extremely low levels of
CCR5 on CD4+ T cells from the blood, lymph nodes and mucosal tissues compared to
CCR5 levels on CD4+ T cells of non-natural hosts (77). Interestingly, both natural and
non-natural hosts exhibit similar levels of CCR5 expression on CD8+ T cells, which calls
to question if low levels of CCR5 expression on natural host CD4+ T cells is an
evolutionary adaptation in response to SIV. Furthermore, several natural host species
(i.e. SM, AGM, mandrills, and sun-tailed monkeys) exhibit extremely low CCR5
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expression levels on CD4+ T cells demonstrating convergent evolution of the natural host
immune system in response to endemic lentiviruses.
It has been speculated that low CCR5 levels on CD4+ T cells may be beneficial to
the host for a number of reasons, such as: (i) a reduction in target cells for virus
replication, and (ii) decreased homing of activated CD4+ T cells to sites of inflammation.
The latter point suggests that low CCR5 levels may also contribute to the low chronic
immune activation state seen in infected natural hosts, since fewer potential target cells
are recruited to sites of inflammation, which are likely sites of active virus replication.
Additionally, low CCR5 levels on CD4+ T cells has been hypothesized to contribute to
non-pathogenicity in natural hosts (75), creating a paradox since infected natural hosts
exhibit robust viral replication. My work addresses in part, mechanisms by which high
viral loads can be sustained in the face of restricted CCR5 expression on natural host
target cells.
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Figure 1-3. Comparison of disease course in HIV/SIV-infected natural and non-natural
hosts. A) Viral and cellular parameters of HIV/SIV infection in non-natural hosts were described
in detail in Fig. 1-1. B) In SIV-infected natural hosts, viral loads peak during acute infection then
decrease to a viral “set point” that persists throughout the lifetime of the infected animal.
Peripheral blood CD4+ lymphocytes transiently decrease during the acute infection then rebound
and are maintained throughout the infection while CD4 T cells in the MALT are severely
depleted and do not rebound to pre-infection levels. Additionally, generalized immune activation
in SIV-infected natural hosts increases during acute infection but is downregulated during the
chronic phase of infection. Paiardini, M. et al. Ann. Rev. Med. 2009.
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HIV/SIV life cycle
HIV/SIV are members of the Lentivirus genus within the Retroviridae family.
Lentiviruses contain a positive-sense, single-stranded RNA genome that is enveloped in a
lipid bilayer derived from the host cell. HIV/SIV particles contain two copies of their
RNA genome enclosed in a capsid core, which is surrounded by a lipid bilayer, studded
with the viral envelope glycoprotein (Env) (43). HIV and SIV genomes are comprised of
nine genes. The structural genes (gag, pol and env) encode proteins required for the
production and assembly of new virion particles, while the accessory genes (tat, rev, nef,
vif, vpr, and vpu [SIVcpz/HIV-1] or vpx [many SIVs/HIV-2]) have regulatory functions,
which affect the synthesis and processing of viral RNA as well as viral infectivity. Long
terminal repeats (LTR) flank the viral genome and play an integral role in the insertion of
the viral genome into the host DNA.
HIV/SIV utilizes CD4 and a co-receptor (chemokine or chemokine-like receptor)
for entry into target cells (21, 26, 29, 36, 62, 86). Steps involved in virus entry will be
discussed in detail in the following section. Once inside the cell, HIV/SIV usurp cellular
machinery for viral propagation, requiring only three additional enzymes, reverse
transcriptase (RT), protease and integrase, which are packaged in the virion capsid and
deposited into target cells upon viral entry. Reverse transcriptase is a RNA-dependent
DNA polymerase, which is extremely error-prone since it lacks proof-reading activity.
RT reverse transcribes the viral RNA genome into a complementary DNA copy, and then
degrades the RNA strand of the RNA/DNA hybrid with its RNase H activity. Cellular
polymerases synthesize the complementary strand resulting in a double stranded DNA
copy of the viral genome. Next, viral DNA is transported to the nucleus where viral
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integrase process the LTRs and catalyze the insertion of the proviral DNA into the host
genome. One characteristic that distinguishes lentiviruses from other retroviruses is their
ability to replicate in non-dividing cells. Integrated proviral DNA is transcribed and
translated generating structural polyproteins, which are processed and used to assemble
new virion particles, as well as copies of full-length viral genomes that are incorporated
into new virions (46). The final steps of the life cycle include budding from the cell
surface and maturation of virion particles, which requires the cleavage of polyproteins
into mature matrix protein by viral proteases.

HIV/SIV entry
HIV/SIV entry into target cells is generally believed to occur via a receptormediated, pH-independent pathway (23). Several chemokine receptors and chemokine
receptor-like proteins mediate HIV/SIV entry in vitro (31), however CCR5 and CXCR4
are thought to play a dominant role in HIV entry in vivo, whereas it is generally accepted
that CCR5 alone mediates SIV entry in vivo (88). HIV/SIV entry mechanisms are
extremely similar; therefore only HIV entry will be discussed in detail.
The viral protein required for target cell entry is the envelope glycoprotein,
gp160, a 160 kDa polyprotein, which is cleaved by cellular proteases to yield two
subunits: (i) gp120, the surface subunit and (ii) gp41, the transmembrane subunit (2, 102,
105). Gp120 and gp41 are non-covalently linked and functionally exist as a trimer of
dimers on the viral particle (49, 64, 66, 103, 107, 108). Each trimer is referred to as an
envelope spike; on average HIV virions are studded with ten envelope spikes (43). The
gp120 subunit is localized on the surface of the viral particle where it can interact with
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cellular receptors. This subunit is composed of five constant regions (C1-C5), which
contain critical domains for binding to entry receptors, as well as five variable regions
(V1 – V5) (71, 106) that can withstand high sequence variability allowing them to act as
immunological shields, protecting the conserved, more critical regions, from antibody
neutralization. In another effort to evade the humoral immune response, gp120 is heavily
glycosylated obscuring much of its surface from antibody recognition (65).
In order for HIV to gain entry into a target cell, the gp120 subunit must first bind
the cellular receptor, CD4 (26, 62). This interaction causes conformational changes in
gp120 resulting in the formation and exposure of the coreceptor binding site (87). The
third variable loop (V3) of gp120 is critical for coreceptor binding. V3 is composed of
three structural regions: (i) the base, which sits closest to the core, (ii) the flexible stem
region, and (iii) the highly conserved tip region. Studies indicate that the base of V3
interacts with the N-terminus of CCR5, while the tip and stem regions of V3 interact with
CCR5 extracellular loops (ECL) (54, 55). Figure 1-4 shows the crystal structure of
trimeric gp120 bound to the CD4 receptor. In this model, the V3 loop of each gp120
monomer is extended towards the cell membrane (55). Upon coreceptor binding,
subsequent conformational changes occur in gp41 exposing the hydrophobic fusion
peptide, which quickly inserts into the target cell membrane (38, 39). Gp41 contains two
heptad repeat regions (HR1 and HR2). Once triggered, HR2 domains in each gp41
subunit fold back on HR1 domains forming a complex (18, 104), the 6-helix bundle,
which brings the viral and target cell membranes into close proximity promoting fusion
through mechanisms that are not fully understood (67). Once fusion occurs, the viral
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capsid core, containing the viral genome, is released into the target cell. HIV receptor
engagement and entry steps are depicted in Figure 1-5.

Figure 1-4. Crystal structure of gp120 trimer with exposed V3 domains conjugated to CD4.
Trimeric model of gp120 where the core (grey) and V3 loops (red) are superimposed onto the
structure of a four-domain CD4 molecule (yellow). In the CD4-triggered state, the V3 domains
protrude 30 angstrom away from the viral envelope and towards the cellular membrane. Image
obtained from Kwong, P. et al. Science 2005.
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Figure 1-5. Model of HIV/SIV entry. A trimeric HIV/SIV Env is shown attached to the viral
membrane. Once the virus comes into close proximity with the cellular membrane, the surface
unit of Env (gp120) binds to the cellular receptor, CD4. Upon binding, conformational changes
occur in Env allowing gp120 to bind to the coreceptor. Gp120/coreceptor engagement causes
subsequent conformational changes exposing the fusion peptide of gp41, which inserts into the
cellular membrane. Formation of the 6-helix bundle brings the viral and cellular membranes into
close proximity, which promotes membrane fusion, ultimately resulting in viral entry. Adapted
from Moore, J.P., Doms, R.W. PNAS 2003.
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HIV/SIV entry coreceptors and tropism
Chemokine receptors are critical for HIV/SIV entry into target cells. These
receptors are members of a large protein family of G protein-coupled receptors (GPCR).
Physiologically, chemokine receptors interact with their cognate ligand, which activates
signaling pathways, ultimately resulting in cell migration. Chemokine receptors are
composed of seven transmembrane helices, which form three extracellular loops, three
intracellular loops, an N-terminus exposed to the extracellular space, and a C-terminus
exposed to the cytosol. Chemokine receptors contain a conserved DRYLAVHA
sequence (“DRY motif”) in the second intracellular loop that has been implicated in Gprotein interaction and signaling. In addition to the role chemokine receptors play in
cellular immunity, these receptors have been extensively studied over the past decade due
to their integral role in HIV/SIV entry.
Various in vitro studies indicate that two particular regions of CCR5 and CXCR4
are critical for HIV entry, the N-terminal domain and extracellular loop two (ECL2).
Studies suggest that tyrosine resides in the N-terminal domain of CCR5 are posttranslationally sulfated; these modifications are critical for high affinity interactions
between the coreceptor and CD4-triggered HIV-1 envelopes (22, 34, 93). As previously
mentioned, the V3 loop plays a central role in coreceptor binding and tropism. Based on
NMR and crystallographic data, Kwong et al. demonstrated that regions of the V3 base
interacted with sulfated tyrosines located in the N-terminus of CCR5 (54). Additionally,
the use of chimeric receptors and site-directed mutagenesis of ECLs revealed that ECL2
also plays a critical role in viral entry (9, 17, 30, 81, 86). Taken together, these studies,
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as well as others, implicate the importance of CCR5 N-terminus and ECL2 in HIV-1
gp120 binding and entry.
Receptor expression is a principal determinant of viral tropism. Early
characterization of HIV entry revealed two viral phenotypes: (i) syncytia-inducing or T
cell-tropic viral isolates that infected primary lymphocytes and lymphocyte cell lines, but
not primary macrophages, and (ii) non-syncytia-inducing or M-tropic viral isolates,
which infected primary macrophages and primary lymphocytes, but not transformed T
cell lines (3, 90, 91, 99). Subsequent studies revealed that differences in target cell
tropism by M-tropic and T-tropic viral isolates was attributed in large part to the cellular
expression of CCR5 and CXCR4 on macrophage and T cell lines, respectively. This
observation lead to the current classification system where HIV viruses are categorized
based on entry coreceptor use: (i) R5 viruses use CCR5 for entry, (ii) X4 viruses use
CXCR4, and (iii) R5X4 or dual-tropic viruses use both CCR5 and CXCR4 (8).
Studies indicate that R5-tropic viruses are commonly transmitted during HIV
infection. These viruses predominate during early infection and exist throughout all
stages of disease. Interestingly, in 50% of HIV infections, R5-tropic viruses acquire the
ability to use CXCR4. Acquisition of CXCR4 use shifts viral tropism from
predominantly CCR5-expressing memory CD4+ T cells to CXCR4-expressing naïve
CD4+ T cells (74, 100), which has been associated with accelerated disease progression
(63).
In contrast to HIV, SIV strains use CCR5 but not CXCR4. However, a number of
additional molecules function in vitro for SIV entry. Based largely on studies using
human molecules, these include CXCR6 (STRL33/Bonzo), GPR15 (BOB), GPR1,
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CCR2, CCR3, CCR4, CCR8 and APJ. As discussed in Chapter 2, CCR2 is thought to be
utilized by SIVrcm in RCM, a large percentage of which lack CCR5 due to a genetic
polymorphism. Otherwise, however, alternative coreceptors have been considered
largely irrelevant to infection in vivo. For many years, alternative coreceptor use by SIV
was considered an in vitro phenomenon, however a number of studies report SIV
replication in T cell lines lacking CCR5, suggesting non-CCR5 entry pathways can
mediate SIV entry (37, 61). My work in Chapter 2 indicates that alternative entry
pathways mediate SIVsmm transmission and replication in vivo (85).

Goals of this thesis
It is well established that SIV infection of natural hosts (African NHP) results in a
non-pathogenic infection, while HIV/SIV infection of non-natural hosts (humans and
Asian NHP) causes pathogenic infections. It appears that natural hosts have developed
several mechanisms to counter the potential pathogenic effects of SIV infection such as
attenuated chronic immune activation, “protection” of critical cell subsets required for
maintenance of the immune system, and the ability to regulate CCR5 expression on
specific cell subsets.
The goal of this thesis is to better understand the underlying mechanisms that
contribute to the non-pathogenic nature of SIV infection in natural hosts. Natural hosts
exhibit significantly lower CCR5 expression on their CD4+ T cells compared to CCR5
expression on CD4+ T cells from non-natural hosts. However both infected natural and
non-natural hosts exhibit robust virus replication. This raises the question where does
robust virus replication come from in infected natural host species since these animals
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exhibit such low CCR5 expression on CD4+ T cells? My work shows that in natural host
SM, non-CCR5 entry pathways can support SIV transmission and replication in vivo. I
then showed that CXCR6 and GPR15 efficiently mediate SIV entry in vitro. Based on
these findings, we hypothesize that alternative coreceptor expression in natural hosts is
restricted to expendable cell subsets that allow robust virus replication without causing
disease.
Next, we sought to study the expression profiles of CXCR6 and GPR15 on human
and SM primary cells. I first set out to examine the expression profile of CXCR6,
GPR15 and CCR5 on various human cell populations since a SM-CXCR6 antibody is not
currently available. This work will serve as a framework for future studies comparing
CXCR6 and GPR15 expression patterns in SM, which we hypothesize evolved to restrict
expression to dispensable cell types.
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Abstract
In contrast to HIV infection in humans and SIV in macaques, SIV infection of natural
hosts including sooty mangabeys (SM) is non-pathogenic despite robust virus replication.
We identified a novel SM CCR5 allele containing a two base pair deletion (∆2) encoding
a truncated molecule that is not expressed on the cell surface and does not support SIV
entry in vitro. The allele was present at a 26% frequency in a large SM colony, along
with 3% for a CCR5∆24 deletion allele that also abrogates surface expression. Overall,
8% of animals were homozygous for defective CCR5 alleles and 41% were
heterozygous. The mutant allele was also present in wild SM in West Africa. CD8+ and
CD4+ T cells displayed a gradient of CCR5 expression across genotype groups, which
was highly significant for CD8+ cells. Remarkably, the prevalence of natural SIVsmm
infection was not significantly different in animals lacking functional CCR5 compared to
heterozygous and homozygous wild-type animals. Furthermore, animals lacking
functional CCR5 had robust plasma viral loads, which were only modestly lower than
wild-type animals. SIVsmm primary isolates infected both homozygous mutant and
wild-type PBMC in a CCR5-independent manner in vitro, and Envs from both CCR5null and wild-type infected animals used CXCR6, GPR15 and GPR1 in addition to CCR5
in transfected cells. These data clearly indicate that SIVsmm relies on CCR5-independent
entry pathways in SM that are homozygous for defective CCR5 alleles and, while the
extent of alternative coreceptor use in SM with CCR5 wild type alleles is uncertain,
strongly suggest that SIVsmm tropism and host cell targeting in vivo is defined by the
distribution and use of alternative entry pathways in addition to CCR5. SIVsmm entry
through alternative pathways in vivo raises the possibility of novel CCR5-negative target
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cells that may be more expendable than CCR5+ cells and enable the virus to replicate
efficiently without causing disease in the face of extremely restricted CCR5 expression
seen in SM and several other natural host species.

Author Summary
SIV causes AIDS in macaques, like HIV-1 does in humans, but not in its natural host
species such as sooty mangabeys (SM). It is therefore important to understand infection
in natural hosts, including the mechanisms and cellular targets of infection. SIV
replication in SM is thought to exclusively use CCR5 as its entry coreceptor, which
mediates viral entry in conjunction with CD4 and is the main determinant of target cell
tropism. However, other molecules also function as SIV coreceptors in vitro. We
discovered that inactivating mutations in the CCR5 gene are common among SM and,
furthermore, homozygous mutant animals lacking functional CCR5 still become infected
and have high viral loads. Ex vivo, SM lymphocytes can be infected independently of
CCR5, and several alternative entry coreceptors are used by SIV from both CCR5+ and
CCR5-null animals. Thus, SIV infection in SM is mediated by other coreceptors in
addition to CCR5, suggesting that these molecules together may determine tropism and
cell targeting in vivo. These results provide new insight into an important model of
nonpathogenic natural host infection, and identify a novel role for alternative entry
pathways suggesting a potentially broader range of target cells in vivo than currently
recognized.
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Introduction
HIV-1 emergence into the human population resulted from cross-species
transmission of SIVcpz from chimpanzees (Pan troglodytes), which itself resulted from
transmission and subsequent recombination of SIVs infecting primates on which
chimpanzees prey (4, 24). Similarly, both simian AIDS caused by SIVmac/smm in
rhesus macaques (RM; Macaca mulatta) and HIV-2 infection of humans originated from
cross-species transmission of SIVsmm from naturally infected sooty mangabeys (SM;
Cercocebus atys) (3, 31, 55). In marked contrast to pathogenic infections leading to
AIDS in non-natural hosts, infection in natural host species including SM is typically
non-progressive (36, 67, 69). Importantly, the benign nature of SM infection in vivo is
not due to overall restricted viral replication, as both nonpathogenic natural host and
pathogenic nonnatural host infections are characterized by robust viremia (11, 32, 59,
68). This observation indicates that immunodeficiency virus replication and pathogenesis
are not inextricably linked. Thus, understanding natural host infection has become a high
priority for identifying key features of infection in vivo that regulate pathogenesis and,
potentially, identify opportunities to modulate disease apart from or in addition to
suppressing overall virus replication through pharmacologic or immune mechanisms.
HIV and SIV entry into target cells is initiated by binding of the viral envelope
glycoprotein (Env) to cell surface CD4, followed by structural changes that enable
interactions with a seven transmembrane G protein coupled cell surface receptor that then
triggers fusion. HIV-1 isolates use CCR5 or CXCR4 or both, and in vitro use other
molecules infrequently. The restricted expression of CCR5 mainly on memory CD4+ T
cells, but broader expression of CXCR4 on both memory and naïve subsets, is thought in
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part to underlie the accelerated disease progression seen in individuals in whom CXCR4using HIV-1 variants emerge late in the course of infection (6, 38, 65, 72). In contrast,
SIV strains use CCR5 almost universally and very rarely use CXCR4. Sooty mangabeys
express very low levels of CCR5 on their CD4+ T cells, a mechanism by which
replication might be regulated in vivo and restrict transmission and pathogenesis (52, 53).
However, most strains of SIV use a number of other alternative coreceptors in in vitro
assays, such as CXCR6 (STRL33), the orphan receptors GPR1 and GPR15, and several
others (18, 21, 61). Despite the efficient use of such alternative entry pathways by
SIVmac and SIVsmm isolates in transfected cells, infection and cell targeting in vivo is
generally thought to be dependent on CCR5 (57). Notably, however, the proportion of
CD4+ T cells depleted and/or infected at a given time in macaques and mangabeys may
exceed the proportion of cells with detectable CCR5 expression, raising the possibility
that other pathways in addition to CCR5 might be utilized (28, 45).
Although both natural and non-natural host infections result in high level virus
replication, several distinguishing features provide probable clues as to possible causes
for the distinct outcomes. It is long believed that in addition to CD4+ T cell destruction,
pathogenesis involves an inability to effectively replenish these populations (29, 46). In
pathogenic rhesus macaque infection, damage to the CD4+ T central memory (Tcm)
subpopulation appears to play a central role in the inability of infected animals to
replenish CD4+ T effector and effector memory (Tem) cells depleted by infection (48).
It has been recently found that cell-associated viral loads in CD4+ Tcm are considerably
lower in SM than RM, despite equivalent or higher Tem infection levels, which might
enable better immune cell homeostasis in infected SM (50). Another difference is the
40

presence of chronic generalized immune activation in infected humans and RM, whereas
natural hosts display generalized immune activation during acute infection that then
rapidly resolves (7, 35, 44, 68). Chronic generalized immune activation may contribute
to accelerated T cell turnover and ultimate depletion, and is believed to result in large part
from translocation of gut microbial products due to gastrointestinal barrier damage during
acute infection (9). However, vigorous virus replication and extensive CD4+ T cell
depletion in gut mucosal tissue occur in both natural and non-natural hosts (10, 28, 54,
73). A potentially important difference is Th17 CD4+ T cells, which play a critical role
in defense against bacteria at mucosal sites, and are lost in HIV-1 and SIVmac rhesus
macaque infection but spared in infected natural hosts (8, 12, 22, 58). Thus, the factors
regulating CD4+ T cell subset targeting in vivo may be central to defining the outcome of
infection in natural or non-natural hosts.
Interestingly, evolution appears to have favored mutations in the CCR5 gene that
abrogate surface expression of this molecule. An allele containing a 32 base pair
frameshift deletion in human CCR5 that abrogates cell surface expression (CCR5∆32) is
present at a frequency of 10% in the Caucasian population, resulting in about 18%
heterozygous and 1% homozygous individuals. CD4+ cells from individuals
homozygous for CCR5∆32 are resistant to infection by CCR5-using HIV-1 isolates in
vitro but permissive for strains that can use CXCR4, and the essential role for CCR5 in
HIV-1 transmission and infection is demonstrated by the finding that individuals
homozygous for CCR5∆32 are highly resistant to infection (43, 63). Furthermore,
heterozygous individuals can be infected but show lower viral loads and slower disease
progression, in association with lower levels of CCR5 expression (17, 33). Red-capped
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mangabeys (RCM; Cercocebus torquatus) are the natural host of SIVrcm, and a 24 base
pair in-frame deletion (CCR5∆24) that also abrogates surface expression is present at an
allelic frequency of 87% (14). As a result, ≥70% of RCM are homozygous for the
mutation and do not express CCR5, and the one known exception to exclusive CCR5
dependence by SIV in vivo is SIVrcm, which uses CCR2b for entry and cannot use
CCR5. The same CCR5∆24 mutant allele was also reported in two different populations
of SM, which are closely related to RCM, but with a low allelic frequency of 4% and no
animals homozygous for the allele were found (14, 51).
In this study, we identified a novel 2 base pair deletion and frameshift mutation in
SM CCR5 (CCR5∆2) that results in a lack of surface expression and coreceptor function.
The mutation is present at a 26% allele frequency in the large Yerkes National Primate
Research Center (YNPRC) SM colony, and together with the previously-described ∆24
allele results in 8% of animals lacking functional CCR5. However CCR5-null SM are
susceptible to natural and experimental SIVsmm infection and exhibit robust viral
replication. This is the first clear evidence for in vivo alternative coreceptor use by
SIVsmm in its natural hosts, which provides an explanation for the efficient use of
alternative coreceptors by the SIVsmm/mac family of viruses. This data also suggests
that cell targeting and tropism in sooty mangabeys is linked to expression and use of both
CCR5 and additional alternative entry pathways, and identifies a third example of
convergent evolution resulting in nonfunctional mutant CCR5 alleles among primate
species.
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Materials and Methods
Ethics Statement
All animal experimentation was conducted following guidelines established by the
Animal Welfare Act and the NIH for housing and care of laboratory animals and performed in
accordance with Institutional regulations after review and approval by the Institutional Animal
Care and Use Committees (IACUC) at the Yerkes National Primate Research Center (YNPRC) or
the Tulane National Primate Research Center (TNPRC). Studies were also reviewed and
approved by the University of Pennsylvania IACUC.

Animals and primary cells
These studies utilized blood cells from animals housed at the YNPRC or TNPRC.
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood using standard
density gradient separation methods. For genomic analysis, approximately 0.8 x 106 PBMC were
lysed in DNA lysis buffer (100 mM KCl; 0.1% NP40; 20 mM Tris pH 8.4; 0.5 mg/ml proteinase
K; 200ul total volume) and used as a template for PCR amplification. For infection studies,
cryopreserved PBMC were thawed under standard conditions and maintained at 106 cells/ml in
RPMI supplemented with 10% FBS, 1% glutamine and 1% penicillin-streptomycin, stimulated
for 3 days with 5 µg/ml of phytohemagglutinin (PHA; MP Biomedical), infected and then
maintained in the same media in the presence of IL-2 (50 U/ml; Novartis). Analysis of wild SM
genotypes was carried out on purified DNA derived from fecal specimens collected in Cote
d’Ivoire, which were previously characterized by mitochondrial DNA sequence analysis to
represent 33 distinct individuals (64).
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Cloning SM CCR5 genes
Full-length SM-CCR5 genes were amplified by PCR from SM genomic DNA using high
fidelity DNA polymerase (Phusion; Finnzymes) and primers based on conserved 5’ and 3’
regions of published SM CCR5 coding sequences (forward: 5’-ATG GAC TAT CAA GTG TCA
AGT CCA ACC-3’; reverse: 5’-TCA CAA GCC AAC AGA TAT TTC CTG CTC C-3’). PCR
reactions contained Phusion polymerase (1 unit) in HF buffer, primers (0.5 uM), dNTPs (0.2 mM)
and 200 ng of purified genomic DNA as template in a 50 ul reaction volume. Thermocycling
conditions: initial denaturation at 98°C for 45 seconds, followed by 20 cycles of 98°C for 10
seconds, 71°C for 30 seconds and 72°C for 90 seconds, with a final extension step of 72°C for 10
minutes. PCR amplicons were column purified (QIAquick PCR Purification kit; Qiagen) and
then used in a second PCR reaction employing primers that incorporated a HindIII restriction site
at the 5’ end of the coding region and a BamHI restriction site at the 3’ end of the CCR5 coding
sequence (forward: 5’-GCT GCT ATA AGC TTC CAC CAT GGA CTA TCA AG-3’; reverse:
5’-AGC GAG CGG ATC CTC ACA AGC CAA CAG ATA-3’; restriction sites underlined).
Thermocycling conditions for the second PCR reaction were: an initial denaturation step at 98°C
for 45 seconds, followed by 5 cycles of 98°C for 10 seconds, 71°C for 45 seconds and 72°C for
60 seconds, followed by 15 cycles of 98°C for 10 seconds, 76°C for 45 seconds and 72°C for 60
seconds, and final extension at 72°C for 10 minutes. CCR5 amplicons were cloned into the
expression plasmid pcDNA3.1+ (Invitrogen) using HindIII and BamHI, and screened by
restriction analysis followed by sequence confirmation. Sequences of the smCCR5∆2,
smCCR5∆24 and smCCR5 wild-type genes cloned here have been deposited in Genbank
(accession numbers HM246694, HM246695 and HM246693, respectively)
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CCR5 genotyping of SM
A two-step PCR-based genotyping assay was developed that identifies CCR5 wild-type
and CCR5∆2 alleles based on differential primer annealing, using genomic DNA from lysates of
SM PBMC. Genomic DNA was subject to PCR amplification using the first round primers
described above, to amplify the entire CCR5 coding region, in reactions that contained Platinum
Taq polymerase (1 unit; Invitrogen), 1.5 mM MgCl2, primers (0.5 uM each), dNTPs (0.2 mM), 13 ul DNA lysate and Taq buffer in 25 ul reaction volumes. Thermocycling conditions were: initial
denaturation at 98°C for 45 second followed by 10 cycles of 94°C for 20 seconds, 68°C for 45
seconds, 72°C for 60 seconds and final extension at 72°C for 10 minutes. The product of this
reaction (2.5 ul) was then used as a template for two separate second-round amplifications, each
of which used a common downstream primer but different upstream primers specific for the wildtype and ∆2 alleles, respectively (forward CCR5 wild-type: 5’-ATC ACT TGG GTG GTG GCT3’; forward CCR5∆2: 5’-ATC ACT TGG GTG GTG CGT-3’; common downstream: 5’-GGT
GTT CAG GAG AAG GAC AAT GTT G-3’). The second round PCR reaction used the same
conditions as the first reaction. Products of the wild-type and ∆2 amplification reactions were
visualized by 2% agarose gel electrophoresis and ethidium bromide staining, which demonstrated
a 325 base pair product following amplification with wild-type or ∆2 primer pairs, or both for
heterozygotes (Figure S1A).
Each animal was also screened for the CCR5∆24 deletion allele with a two-step PCRbased assay. Products of the first round PCR reaction described above, were subjected to nested
amplification with inner primers (forward: 5’-GGC TAT CGT CCA TGC TGT GT-3’; reverse:
5’-GAC CAG CCC CAA GAT GAC TA-3’) and thermocycling conditions as follows: initial
denaturation at 94°C for 45 seconds, followed by 25 cycles of 94°C for 20 seconds, 59°C for 45
seconds, 72°C for 60 second, and a final extension at 72°C for 10 minutes. Products were
visualized by 3% agarose gel electrophoresis and ethidium bromide staining, yielding a 205 base
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pair product from the ∆24 allele, which was easily distinguishable from the 227-229 bp product
from the wild-type and CCR5 ∆2 alleles (Figure S1B).
As a secondary confirmation of genotypes established by PCR screening, direct bulk
sequencing was carried out on PCR amplified genomic DNA. Amplification was done using the
outer primer set as described above, except that Phusion high fidelity polymerase was used for 30
cycles. Products were column-purified and sequenced. Genotypes were verified by manual
inspection to confirm the presence of uniform sequences for homozygous animals, or detection of
expected frameshifts resulting in overlapping sequences for heterozygous animals (Figure S1C).
For fecal-derived samples, 0.5 ug of purified DNA (of which only a fraction reflected
host-derived DNA) was PCR amplified for 35 cycles using first round outer primers as described
above, and then subjected to nested amplification for 30 cycles using the inner primer set
described above. Products were then subjected to direct sequence analysis.

Pseudotype luciferase reporter virus infections and coreceptor use analysis
SIVsmm Env-mediated entry was analyzed using luciferase-expressing reporter viruses
pseudotyped with envelope glycoproteins of interest. Pseudotype viruses were generated by cotransfecting 293T cells with a plasmid encoding the NL4-3-based env-deleted luciferaseexpressing virus backbone (pNL-luc-E–R+) (16) along with expression plasmids encoding
SIVsmm, SIVmac, HIV-1 or VSV-g envelope glycoproteins. Cells were transfected overnight
using Fugene (Roche) and washed the next day to remove residual transfection reagent.
Supernatants were collected 2 days later, clarified by centrifugation and stored at -80°C until use.
Pseudotype viruses were quantified based on HIV-1 Gag p24 antigen ELISA (PerkinElmer) and
virion infectivity measured on U87 cells stably expressing CD4 and CCR5. Inocula were then
standardized on the basis of infectivity in U87/CD4/CCR5 cells (1x106 relative light units; RLU).
The ability of pseudotype viruses to use different coreceptors was assayed in target 293T
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cells expressing CD4 and the coreceptor of interest. Target cells were prepared by cotransfection with expression plasmids carrying CD4 and the desired co-receptor (1ug of each
plasmid) using Fugene. Cells were re-plated one day post-transfection at 2x104 cells/well in 96well plates and then infected the following day with pseudotype reporter viruses using equivalent
inocula (1x106 RLU) by spin inoculation for 2 hours at 1200G. Three days later cells were lysed
(0.5% Triton X-100 in PBS) and infection quantified on the basis of luciferase production in
target cells, determined by adding an equal volume of luciferase substrate (Promega) and
measuring luciferase activity in RLU with a luminometer.

SIV envelope clones and infectious viruses
SIV envelopes used in pseudotype infections were generated from plasma of SIVsmminfected CCR5 wild-type (FFv) and ∆2 homozygous (FNp) SM by single genome amplification
(SGA) using methods and protocols previously described and cloned into pcDNA3.1 using Topo
TA (Invitrogen) (41, 60). Infectious SIVsmm strains M923 and M951 were isolated as
previously described (25) and stocks were prepared in primary SM PBMC.

FACS analysis of wild-type and mutant CCR5 surface expression
293T cells were transfected with wild-type or mutant forms of CCR5 using Fugene
according to manufacturer’s instructions. One day later cells were detached by incubation in PBS
containing 2 mM EDTA, washed in FACS buffer (PBS containing 1% FBS and 0.1% sodium
azide), and stained with the CCR5 monoclonal antibody, clone 3A9-[APC] (BD Pharmingen) or
isotype-matched control. Cells were analyzed using a FACS Caliber flow cytometer (BD
Biosciences) and FloJo software (Tree Star, Inc.) to determine CCR5 surface expression.
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SIV infections of primary SM PBMC
PHA-stimulated SM PBMC were plated in 96-well plates at 2.5 x 105 cells/well,
incubated for 1 hour in the presence or absence of the CCR5 antagonist maraviroc (15 uM;
Pfizer), and then infected with SIVsmm strains (M923 and M951) by spin inoculation (1200xg
for 2 hours) followed by overnight incubation. The next day cells were washed in PBS and
maintained in media containing IL-2 (50 U/ml), with or without maraviroc (15 uM). Cell
supernatants were collected periodically for 3 weeks and replication measured by SIV Gag p27
antigen in cell supernatant by ELISA (Advanced BioScience Laboratories).

Analysis of SM virological and immunological parameters
Clinical data on infected and uninfected SM housed at YNPRC has been reported
previously for surveys carried out in 2004-5 and 2006-7 and 2008-9 (70). CD3, CD4 and CCR5
expression on PBMC were analyzed by FACS and plasma viral loads were measured by real-time
PCR as described (68, 70). For purposes of analysis, any undetectable viral loads were set at 75
copies, the lower limit of detection. In cases where animals seroconverted during the period of
observation, data from prior to infection was included with uninfected animals, while data from
after infection was included with infected animals. If multiple measurements were available for
individual animals for any parameters, mean values were utilized.
Statistical Analysis
Virological and immunological data were compared between genotype groups using
ANOVA or Kruskal-Wallis test followed by the Dunn’s multiple comparison test for multiple
groups. The two-sample proportions test and Chi-Square test were used for comparison between
independent groups. Statistical tests were performed using Prism 4.0 software and OpenEpi:
Open Source Epidemiologic Statistics for Public Health, Version 2.3. Data were considered
significant when P-value was below 0.05.
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Results
Identification of a novel mutation in the sooty mangabey CCR5 gene
We amplified the CCR5 coding sequence from SM genomic DNA, cloned it into
an expression vector and analyzed several clones by sequence analysis. Cloning from
four independent PCR reactions amplifying smCCR5 from one animal (FVq) resulted in
the identification of two distinct alleles in each of the PCR amplifications (Figure 2-1).
One was a wild-type allele, similar to published smCCR5 sequences (smCCR5 wt), and
the other was a novel allele containing a two base pair deletion at nucleotides 466 and
467 of the coding sequence (smCCR5∆2), which corresponds to the fourth
transmembrane domain (TM4) of the smCCR5 protein (Figure 2-1A). This deletion
causes a frameshift that results in a predicted protein with 110 missense amino acids prior
to termination at residue 265 (Figure 2-1B). In addition to this deletion, the smCCR5∆2
allele contains two nucleotide substitutions compared with the wild-type allele identified.
The first is a 436T>G substitution resulting in a L146V amino acid change, which is also
found in several published wild-type smCCR5 sequences. The second nucleotide
substitution is 538C>T, but is masked in CCR5∆2 due to the frameshift.
In addition to premature truncation of the protein, the mutation results in several
charged amino acids predicted within TM4, as well as loss of both disulfide bonds
(between the N-terminus and third extracellular loop (ECL), and between the first and
second ECLs, respectively) that maintain secondary structure. These features suggest
that the mutant protein is unlikely to be configured in a manner to allow proper
membrane placement and either normal signaling or SIV/HIV entry coreceptor function.
There are several other mutations in primate CCR5 genes, including the well49

studied 32 base pair frameshift mutation in human CCR5 (CCR5∆32) (17, 43, 63) and a
24 base pair deletion (CCR5∆24) that is common in RCM and also reported at low
frequency in SM (14, 51). Therefore, we examined the relationship between this SM
CCR5∆2 deletion and the ∆24 RCM/SM and human ∆32 deletions (Figure 2-1A & B).
The smCCR5∆2 deletion occurs in the same region of TM4, and overlaps the ∆24
deletion, which is characterized by multiple G-T-G repeats. In contrast, the human
CCR5∆32 deletion occurs approximately 90 bases downstream of smCCR5∆2, within the
second extracellular loop of the protein. Interestingly, the SM and RCM ∆24 alleles also
contain the 436T>G and 538C>T substitutions seen smCCR5∆2, which result in amino
acids identical to those in human CCR5 at those respective sites (valine at position 146
and serine at position 180; Figure 2-1B).
Because the CCR5∆24 mutation was previously reported to be present in animals
at YNPRC (51), animals were screened for its presence by PCR and several ∆24 carriers
were identified (Figure 2-S1). We therefore generated a clone of the CCR5∆24 coding
region by PCR of genomic DNA from one heterozygous animal. Sequence analysis of
this CCR5∆24 clone was similar to the sequence previously described (14, 51), except for
a non-coding 1026G>T substitution.
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Figure 2-1. Sequence alignment of wild-type and mutant CCR5 genes.
(A) Partial nucleotide sequence alignment and (B) predicted protein sequence alignment of the
wild-type smCCR5 and smCCR5∆2 alleles (GenBank HM246693 and HM246694), the
CCR5∆24 alleles previously described in sooty and red capped mangabeys (GenBank AF07473
and AAC62474), and human wild-type CCR5 and CCR5∆32 alleles (GenBank DQ217934 and
U66285). Residues identical to the wild-type smCCR5 molecule are indicated by ‘.’ and gaps are
shown as dashes. Location of the frameshift resulting from the smCCR5∆2 deletion in TM4 is
indicated by an inverted black triangle while the huCCR5∆32 frameshift is indicated by an
inverted white triangle. Transmembrane domains are indicated by shaded boxes and mis-sense
amino acid sequences resulting from mutations are highlighted.
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Cell surface expression of mutant smCCR5∆2
Previous studies have shown that proteins encoded by the mutant human
CCR5∆32 and RCM/SM CCR5∆24 are not expressed on the cell surface (51, 63). To
test whether the smCCR5∆2 mutant gene gave rise to a protein expressed on the cell
surface, we transfected 293T cells with wild-type and mutant SM CCR5 expression
plasmids, along with human CCR5, and measured surface expression by flow cytometry.
Staining utilized mAb 3A9, which cross-reacts with both human and SM CCR5 and,
importantly, recognizes an epitope in the N-terminus that is upstream of the mutation and
should be detected if the predicted protein were expressed.
As shown in Figure 2-2, surface expression of CCR5 was readily detected on
cells transfected with SM or human wild-type CCR5. In contrast, neither the ∆2 nor ∆24
SM mutant CCR5 alleles gave rise to detectable surface expression. We have so far been
unable to assess intracellular expression because of high nonspecific intracellular staining
with 3A9 and other anti-N-terminal CCR5 antibodies in all cells tested so far (data not
shown). From this data, we conclude that the frameshift mutation in smCCR5∆2 results
in a truncated protein that is not expressed on the cell surface. In addition, our
observation that the CCR5∆24 mutant allele is not expressed at the cell surface is
consistent with previous reports that this deletion abrogates cell surface expression even
though it is not a frameshift (14, 51). We also asked if the mutant protein might have a
dominant negative effect on wild-type CCR5 expression, but found no change in CCR5
staining if the wild-type CCR5 plasmid was co-transfected along with the ∆2 or ∆24
alleles (Figure 2-S2).

53

Figure 2-2. Surface expression of wild-type and mutant CCR5 variants in vitro.
293T cells were transfected with expression plasmids encoding smCCR5 wild-type (orange),
smCCR5∆2 (light blue), smCCR5∆24 (magenta) and huCCR5-wt (green), along with empty
expression plasmid (dark blue). Untransfected 293T cells (shaded red) serve as controls. Cells
were stained with an anti-CCR5 mAb (clone 3A9; APC-conjugated), which recognizes the Nterminal region of both human and sooty mangabey CCR5 (right panel), or an isotype-matched
control antibody (left panel).
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Prevalence of the smCCR5∆2 allele in the YNPRC sooty mangabey population
Next we determined the prevalence of the smCCR5∆2 allele in SM housed at the
Yerkes National Primate Research Center (YNPRC), which is the largest captive colony
of SM in the world (n=202). All animals were initially screened using a discriminatory
PCR assay that specifically identifies the smCCR5 wild-type and ∆2 alleles (Figure 2S1A). Animals were also screened for the ∆24 allele using primers that discriminate ∆24
from ∆2 and wild-type alleles based on amplicon size (Figure 2-S1B). Results were then
verified by direct bulk sequencing of genomic DNA amplicons that confirmed the
presence or absence of homozygous genotypes, or demonstrated frameshifting with
sequence overlap in heterozygous animals (Figure 2-S1C).
The result from this analysis is shown in Table 2-1. Five of six possible
genotypes were identified: 50.5% of the SM carried two wild-type CCR5 alleles; 37.6%
were heterozygous for wild-type and ∆2 alleles, and 4% of the SM were heterozygous for
the wild-type and ∆24 alleles. Notably, 6.4% of the SM were homozygous for the
smCCR5∆2 allele, and 1.5% carried both ∆2 and ∆24 mutant alleles (Table 2-1). Thus,
nearly 8% of animals carry two CCR5 mutant alleles encoding defective CCR5 proteins.
We did not identify any SM that were homozygous for the ∆24 allele.
In this SM population, analysis of allelic frequencies showed 26% of alleles
carried the novel ∆2 deletion, 3% carried the ∆24 deletion, and 71% were wild-type. Of
note, the 3% frequency we found for the ∆24 allele is similar to the 4% allelic frequency
described 12 years ago among SM housed at YNPRC (51). We then used the allelic
frequencies to calculate a predicted genotype distribution (Table 2-1 and Table 2-S1).
There was close agreement between predicted and observed genotypes (p=ns; Chi-square
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test), suggesting that the CCR5 alleles are in equilibrium in this population (of which
~60% are SIV-infected), without evidence of selective pressure favoring or disfavoring
any of the genotypes.

Table 2-1. Genotypic frequencies in Sooty Mangabeys at YNPRC

1

Genotype:

n

Observed frequency (%)1

Predicted frequency (%)2,3

W/W

102

50.5

50.8

W/∆2

76

37.6

37.1

W/∆24

8

4.0

3.9

∆2/∆2

13

6.4

6.8

∆2/∆24

3

1.5

1.4

∆24/∆24

0

0

0.1

Total

202

Genotype distribution among all sooty mangabeys was determined by PCR and direct
genomic sequence analysis

2

Predicted genotype distribution was calculated by Punnett square analysis, based on
allelic frequencies (W=0.71; ∆2=0.26; ∆24=0.03) derived from observed genotypes.

3

Observed and predicted genotype frequencies are not significantly different (Chi-square
test)
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Prevalence of mutant CCR5 alleles in other captive and wild African sooty
mangabey populations
The YNPRC colony is the largest population of SM in the US and the close match
between predicted and observed CCR5 genotype distributions suggested an absence of
selective pressure for or against any specific genotype. However, we wished to
determine the frequency with which these alleles and genotypes were present in other SM
populations, so we analyzed genomic DNA obtained from 29 animals housed at the
Tulane National Primate Research Center (TNPRC). Of note, many of the monkeys that
founded the TNPRC colony originally came from YNPRC in the 1980s, but have been
housed and bred separately since then. In this smaller population the ∆2 allele was
present at a frequency of 19% and the ∆24 allele had a frequency of 5%. As shown in
Table 2-2 and Table 2-S2, the observed genotype frequencies in this population also do
not differ from those predicted by allele frequencies.
We also asked whether the CCR5∆2 allele was present in SM in Africa. For this
analysis we amplified CCR5 genes from fecal-derived host DNA samples from 33 wildliving animals in the Tai forest of Cote d’Ivoire (64). Five animals carried both the
CCR5∆2 and wild-type alleles, and in one animal only the ∆2 allele was detected. An
additional 2 animals carried both ∆24 and wild-type alleles, while the remaining animals
revealed only wild-type sequences. Because this analysis utilized fecal DNA containing
limiting quantities of host DNA, we can only be certain that both alleles were captured if
animals were found to be heterozygous. Thus, while it is not possible to determine a
precise allele frequency, these genotypes suggest a minimum allele frequency of 9% for
CCR5∆2 and 3% for CCR5∆24 in this population. This result indicates that the ∆2 allele
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is also present in wild-living SM in Cote d’Ivoire, although likely at a lower frequency
than in captive animals at YNPRC.

Table 2-2. Observed and predicted genotype frequencies in Sooty Mangabeys
housed at the TNPRC1
Genotype:

n

Observed frequency (%)2

Predicted frequency (%)3,4

W/W

18

62.1

57.6

W/∆25

7

24.1

28.8

W/∆24

1

3.4

7.8

∆2/∆2

1

3.4

3.6

∆2/∆24

2

6.9

2.0

∆24/∆24

0

0.0

0.3

Total

29

1

All animals except one are SIV-infected

2

Genotype distribution among all sooty mangabeys was determined by PCR and direct
genomic sequence analysis

3

Predicted genotype distribution was calculated by Punnett square analysis, based on
allelic frequencies (W=0.76; ∆2=0.19; ∆24=0.05) derived from observed genotypes.

4

Observed and predicted genotype frequencies are not significantly different (Chi-square
test).

5

Includes one SIV-negative animal.

58

Expression of CCR5 on SM CD4+ and CD8+ T cells ex vivo
Since overexpression studies in transfected cells suggested that neither this
common smCCR5∆2 nor the less common ∆24 proteins are expressed on the cell surface,
we examined the relationship between genotypes and CCR5 expression on primary SM
CD4+ and CD8+ T cells. To address this point, we analyzed CCR5 expression data that
was available from animals housed at the YNPRC collected during periodic surveys
between 2004 and 2009, focusing on uninfected animals, and grouped individuals
according to their CCR5 genotypes. Since neither ∆2 nor ∆24 CCR5 alleles express
following transfection, the two mutations were combined for the purposes of this analysis
into a homozygous wild-type, heterozygous, and homozygous deletion allele groups
(Figure 2-3).
As previously reported (52) and as shown in Figure 3, CCR5 expression is
markedly greater on SM CD8+ T cells than CD4+ T cells. In both populations there was
a gradation in the percentage of cells staining positive for CCR5 that correlated with
CCR5 genotype status. The difference was particularly evident for CD8+ T cells, and the
percentage of CCR5+/CD8+ T cells was 9.9%, 5.4% and 0.8% for wild-type,
heterozygous and homozygous mutant groups, respectively (Figure 3A; p<0.0001 by
Kruskal-Wallis test). This finding indicates that the CCR5∆2 genotype acts as a
determinant of CCR5 expression on CD8+ T cells. There was also a strong linear
relationship between wild-type gene dosage and CCR5 expression for CD8 cells
(R2=0.99996; p=0.009 by Pearson’s 2-tailed correlation coefficient), consistent with the
absence of a dominant negative effect by the mutant alleles in transfected cells (Figure
S2). A trend was also evident for CCR5 staining on CD4+ T cells among the three
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groups (2.8%, 1.7% and 1.2% in the wild-type, heterozygous and homozygous mutant
groups, respectively), which did not reach statistical significance (p=ns by KruskalWallis test) but is consistent with the notion that, although overall very low, CCR5
expression on CD4+ T cells is also regulated by CCR5 genotype.
Representative FACS plots showing CCR5 expression on CD4+ and CD8+ T
cells from a homozygous wild-type, heterozygous and homozygous mutant animal are
shown in Figure 2-3B. We think the low level (~1%) of cells within the CCR5 gate for
homozygous mutant animals likely represents background staining, rather than low levels
of N-terminal expression given the result of transfection studies (Figure 2-2).
Unfortunately, antibodies available that are directed at other epitopes in human CCR5 do
not recognize SM CCR5.
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Figure 2-3. CCR5 surface expression on sooty mangabey CD4+ and CD8+ T cells ex vivo.
(A) CCR5 staining on CD8+ T cells (left) and CD4+ T cells (right) of uninfected sooty
mangabeys was carried out between 2004 and 2009, and analyzed according to genotype groups
(mean ± SEM): CCR5 wild-type (W/W; n=38), heterozygous (W/∆; n=34) and homozygous
mutant (∆/∆; n=7). Because both ∆2 and ∆24 alleles are functionally null, they were combined
for this analysis. CCR5 expression by CD8+ T cells differs significantly between genotype
groups (p<0.0001 by Kruskal-Wallis test), while the trend for CD4+ T cells does not reach
statistical significance (p=ns). (B) FACS plots showing CCR5 staining on CD4+ and CD8+ T
cells from representative homozygous wild-type, heterozygous and homozygous mutant animals.
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CCR5-null genotype does not protect sooty mangabeys from SIVsmm infection in
vivo
In humans, the CCR5∆32 homozygous genotype provides powerful protection
against HIV-1 infection (17, 43, 63). Therefore, we asked if animals homozygous for
CCR5-null alleles were infected by SIVsmm. In order to more properly assess natural
susceptibility, we restricted this analysis to YNPRC animals that were naturally infected
(n=120) and those with documented SIV-negative status (n=72), and excluded animals in
the colony known to have been experimentally infected (n=10).
As shown in Table 2-3, we found that among SM with the CCR5 homozygous
wild-type genotype, 65% were naturally infected while 35% were uninfected, and 62% of
CCR5 heterozygous animals were infected and 38% were uninfected. Unexpectedly,
among animals homozygous for CCR5-null alleles (n=14), 50% were naturally infected
and 50% were seronegative. Thus, animals lacking functional CCR5 genes are
susceptible to natural SIVsmm infection. The slightly lower prevalence of SIV infection
among animals in the CCR5-null group was not statistically significant (p=ns; Chi-square
test). We also compared the distribution of genotypes within the SIV-negative and
naturally-infected SIV populations (Table 2-4). Similarly, there were no significant
differences in genotype distribution between the SIV serostatus groups (p=ns for each
genotype group; 2-sample proportions test), although a slightly lower proportion of
homozygous CCR5 mutant animals was seen in the infected animals compared with SIVnegative animals (5.8% vs. 9.7%; p=ns). Therefore, the CCR5-null genotype does not
prevent natural acquisition of SIVsmm infection. Furthermore, neither heterozygosity
nor homozygous null genotype appears to significantly influence SM susceptibility to
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SIVsmm infection in vivo, and while we cannot absolutely rule out a small effect, any
protection that might be afforded by CCR5-null status would be slight. This result stands
in marked contrast to the profound protective effect of CCR5∆32 homozygosity in
humans.
We also determined the genotypes of 10 animals at YNPRC that were infected
experimentally. Five of these animals were homozygous for the CCR5 wild-type gene,
three were heterozygotes (all W/∆2) and two were homozygous for smCCR5∆2.
Furthermore, all but one of the TNPRC animals studied are SIVsmm-infected, including
a mix of both natural infections and experimental inoculation done in earlier decades.
Among the infected animals were three homozygous CCR5-null animals, while the one
uninfected animal was heterozygous (W/∆2). Therefore, SM naturally deficient in CCR5
expression are susceptible to experimental as well as natural SIVsmm infection,
confirming that non-CCR5 entry pathways can mediate SM natural host infection.
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Table 2-3. Prevalence of naturally-acquired SIV infection among YNPRC sooty
mangabeys based on CCR5 genotype.
Genotype1

SIV positive2 (n)

SIV negative3 (n)

% SIV infected4

W/W

63

34

65

W/∆

50

31

62

∆/∆

7

7

50

Total

120

72

63

1

CCR5∆2 and ∆24 alleles were grouped together as defective for expression (∆)

2

Includes animals known to be infected naturally in the wild or in captivity, and excludes

10 animals infected experimentally
3

Includes animals known to be SIV-negative at the time of last survey

4

SIV prevalence does not differ significantly among the genotype groups (Chi-square

test).
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Table 2-4. Genotypic distribution among YNPRC sooty mangabeys based on SIV
infection status
Genotype1

SIV positive SM (n=120)2,4

SIV negative SM (n=72)3,4

W/W

0.525

0.472

W/∆

0.417

0.431

∆/∆

0.058

0.097

1

CCR5∆2 and ∆24 alleles were grouped together as defective for expression (∆).

2

Includes animals known to be infected naturally in the wild or in captivity, and excludes

10 animals infected experimentally.
3

Includes animals known to be SIV-negative at the time of last survey

4

Differences in genotype distribution among animals based on SIV infection status are

not statistically significant (2-sample proportions test).

Influence of smCCR5 genotype on plasma viral loads and CD4 counts in SIVsmminfected SM
We next asked if CCR5 genotype affected plasma viral loads in infected animals.
Based on previously collected data, the log10 viral load (mean ± SEM) was calculated for
animals in each genotype group; for animals with multiple data points available, their
mean viral load (log10) was used (Figure 2-4). This analysis showed robust viral loads in
all genotype groups, with a modest but statistically significant gradient in VL dependent
on the presence of a wild-type CCR5 allele (p=0.005 by Kruskal-Wallis test). Animals
possessing two wild-type alleles exhibited the highest viral load (4.83 ± 0.10 log10),
65

heterozygotes showed an intermediate level (4.65 ± 0.10 log10), and infected animals with
the CCR5-null genotype had the lowest VL (4.37 ± 0.15 log10). Thus, there is
approximately 0.5 log10 difference in viral load in animals with two wild-type compared
with two CCR5-null alleles. The two important points here are that homozygous mutant
animals have vigorous viral replication despite lacking functional CCR5, and
simultaneously exhibit a small but significant difference in plasma viral load associated
with increasing CCR5 gene dosage.
CD4 counts remain stable during chronic SIVsmm infection in the vast majority
of animals, but some exceptions have been noted (2, 47), so we next asked if SIVinfected animals exhibit differences in CD4 counts depending on their CCR5 genotype.
However, there was no significant difference in CD4+ T cell levels among the genotype
groups, whether assessed based on absolute counts (Figure 2-S3A; p=ns, KruskalWallis) or on the basis of CD4 percentage (Figure 2-S3B; p=ns, ANOVA). These
results suggest that CD4+ T cell levels are maintained similarly in SIV-infected SM
regardless of CCR5 genotype.
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Figure 2-4. SIV plasma viral load measurements in infected sooty mangabeys between
genotype groups.
Plasma viral load measurements (VL log10; means ± SEM) collected in surveys carried out
between 2004 and 2009 of infected animals in the wild-type (n=60), heterozygous (n=49), and
homozygous mutant (n=7) genotype groups. The ∆2 and ∆24 alleles were combined for this
analysis. The difference in VL between homozygous wild-type and CCR5-null genotype groups
(W/W vs. ∆/∆) is statistically significant (p<0.05; Dunn’s multiple comparison test) whereas the
differences for the heterozygous group (W/∆ vs. W/W; W/∆ vs. ∆/∆) does not reach statistical
significance (p=ns; Dunn’s multiple comparison test).
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smCCR5∆2 does not support SIV entry in vitro
We then asked if there was any chance that the smCCR5∆2 mutant allele, when
expressed along with CD4, could support SIV infection in vitro. We considered it
unlikely but thought it was necessary to test directly given the staining patterns by CCR5
mAb 3A9 in ∆2 homozygous primary mononuclear cells (Figure 2-3). We also
considered it important to test using SIVsmm from a CCR5∆2 homozygous infected
animal, in case viral adaptation might have enabled use of an N-terminal region alone.
Therefore, we generated pseudotype virions carrying Env glycoproteins cloned directly
from plasma virus of an SIVsmm-infected CCR5∆2 homozygous animal (FNp), along
with pseudotypes carrying Envs cloned from plasma of an infected wild-type animal
(FFv). Use of plasma virus ensured that these Envs were derived from actively
replicating virus. Target 293T cells were co-transfected with CD4 plus plasmids
encoding wild-type smCCR5, smCCR5∆2, human CCR5 or an empty vector as a control,
then infected with the primary SIVsmm pseudotypes. Of note, pseudotype virions
carrying the FNp 5.1 Env were considerably less infectious than the other Envs and very
large amounts of this virus were required to achieve equivalent infectious inocula, which
generally resulted in high levels of background for this Env.
As shown in Figure 2-5, wild-type smCCR5 and human CCR5 support infection
of all SIVsmm variants to similar levels. In contrast, the smCCR5∆2 allele does not
support infection by any of the viruses. Importantly, CCR5∆2 does not function as a
coreceptor for Env variants from CCR5-null animals. Thus, SIVsmm infections in
CCR5-null animals are mediated through pathways independent of CCR5.

68

Figure 2-5. Mutant smCCR5∆2 does not support SIV infection in vitro.
293T cells were transfected with CD4 alone (yellow bars) or in combination with wild-type
smCCR5 (blue bars), smCCR5∆2 (green bars) or wild-type human CCR5 (red bars). Target cells
were infected with luciferase-expressing pseudotype virions carrying Env glycoproteins that were
cloned from plasma of two SIVsmm-infected sooty mangabeys (FFv: W/W SM; FNp: ∆2/∆2
SM). Pseudotypes carrying the R5-tropic HIV-1 Env JRFL and virions lacking envelope
glycoproteins served as controls. Infection was measured by relative light units (RLU) in cell
lysates 3 days after infection (mean ± SD).
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Use of alternative coreceptors by SIVsmm isolates
The data presented here indicates that SIVsmm must be able to use entry
pathways other than CCR5 for replication in vivo. It is long known that many SIV strains
use a number of alternative coreceptors in addition to CCR5 in vitro, although these
viruses rarely use CXCR4. We therefore tested the ability of SIVsmm envelopes to
mediate infection through human CCR2b, CCR3, CCR8, GPR1, GPR15 (BOB), CXCR6
and CXCR4. This analysis employed the uncultured SIVsmm envelope glycoproteins
cloned from plasma of the CCR5-null (FNp) and homozygous wild-type (FFv) infected
animals.
As shown in Figure 2-6, all SIVsmm envelope glycoproteins tested mediated
entry into cells expressing CD4 in conjunction with GPR15 and CXCR6, while GPR1
was also used but less efficiently. In contrast, none of the SIVsmm envelope
glycoproteins could use CXCR4 as a coreceptor, nor CCR3 or CCR8 (data not shown).
Interestingly, SIVsmm envelope glycoproteins failed to use CCR2b, an entry pathway
employed by SIVrcm in RCM that typically lack CCR5 due to a high prevalence of the
∆24 mutation (14). Furthermore, the patterns of alternative coreceptor use were similar
for envelope glycoproteins derived from CCR5-null and CCR5 wild-type animals,
indicating that alternative coreceptor utilization is a feature shared by SIVsmm regardless
of whether the host animal expresses CCR5. While absolute luciferase production varied
among experiments, GPR15 and CXCR6 typically supported levels of infection similar to
that mediated by CCR5 (Figure 2-S4), although transfected targets likely represent
maximum levels of potential utilization relative to primary cells that would express these
molecules at physiological levels.
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Figure 2-6. Alternative coreceptor utilization by SIVsmm Envs in vitro.
293T cells were transfected with CD4 alone or in combination with (A) the alternative
coreceptors GPR1, GPR15 and CXCR6, or (B) CXCR4, CCR2b or CCR5. Target cells were then
infected with luciferase-expressing pseudotype virions containing SIVsmm Envs from infected
CCR5 wild-type (FFv: W/W SM) and CCR5-null (FNp: ∆2/∆2 SM) animals. Envs from
SIVmac239, HIV-1 JRFL and virions lacking Env served as controls. Infection was assayed by
RLU (mean ± SD) measured 3 days after infection.
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SIVsmm infects sooty mangabey CCR5-null primary PBMC in vitro and infection of
wild-type PBMC is not blocked by the CCR5 antagonist maraviroc
We next investigated the role of non-CCR5 pathways in SIVsmm infection of
primary SM cells, utilizing both the specific CCR5 antagonist maraviroc and CCR5-null
PBMC derived from CCR5∆2 homozygous animals. Maraviroc blocks chemokine
signaling and HIV-1 Env entry through human and rhesus macaque CCR5 (37, 62), but
blocking of SM CCR5 coreceptor function has not been reported. Therefore, we first
tested the effect of maraviroc on SIVsmm entry through smCCR5 in transfected cells. As
shown in Figure 2-7A, maraviroc blocked SIVsmm pseudotype infection of target cells
expressing CD4 and smCCR5, reducing luciferase expression to the level seen with target
cells expressing CD4 alone (data not shown), indicating complete blocking of smCCR5mediated entry by maraviroc. In contrast, maraviroc did not inhibit SIVsmm entry
mediated by GPR15 (Figure 2-7A), nor did it affect entry by VSV-G pseudotypes (data
not shown), confirming that blocking is not a nonspecific effect.
Next we asked if maraviroc would affect productive infection of SM primary
PBMC by infectious isolates of SIVsmm. PBMC from an uninfected CCR5 wild-type
(FAk) and a CCR5-null (FAz) animals were activated with PHA for three days, and then
infected in the presence and absence of maraviroc with two SIVsmm primary isolates
(M923 and M951), which were both derived from CCR5 wild-type infected animals.
Viral replication was measured as SIV gag p27 levels in supernatants collected
periodically post-infection (Figure 2-7B).
We first noted that both SIVsmm isolates were able to productively infect primary
PBMC in vitro from the CCR5-null SM (FAz). In these cells, there was no difference in
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replication associated with CCR5 blocking by maraviroc, as expected given the lack of
functional CCR5 encoded by the mutant genes. This result indicates that SIVsmm
infection of CCR5-null PBMC can occur independently of CCR5. We then tested CCR5
wild-type PBMC (FAk), and found that SIVsmm established productive infection in both
the absence and presence of maraviroc. Furthermore, there was no difference in the level
of infection achieved when CCR5 was blocked, based on p27 antigen production. This
finding indicates that SIVsmm efficiently enters even CCR5-expressing SM primary
PBMC through pathways independent of CCR5.

CCR5 genotypes in sooty mangabeys with SIV evolution to X4 coreceptor use
Unlike HIV-1 in humans, CXCR4 use by SIV in SM is rare. However, a few
exceptions have been noted in which CXCR4 use emerged following experimental
infection, which was associated with profound CD4+ T cell loss although not clinical
AIDS (47). Therefore, to ask if restricted CCR5+ target cell availability due to genetic
absence of the coreceptor might be linked to CXCR4 emergence, we genotyped two
infected CD4-low SM previously described in which CXCR4-using SIVsmm variants
emerged (47). Neither animal possessed a CCR5-null genotype: one was CCR5
homozygous wild type and the other was heterozygous for the CCR5∆2 allele. Thus, the
fact that acquisition of CXCR4 use by SIVsmm can occur but is not associated with
animals that genetically lack CCR5 is consistent with the notion that alternative pathwaysupported entry in vivo is robust and lack of CCR5 does not serve as a driving force in the
rare cases with emergence of CXCR4 use.
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Figure 2-7. Effect of CCR5 blocking on SIVsmm use of CCR5 and entry into primary SM
PBMC.
(A) 293T cells were transfected with CD4 in combination with wild-type smCCR5 or GPR15.
Two days post-transfection, target cells were pretreated for one hour with or without the CCR5
antagonist, maraviroc (15uM), and then infected with pseudotype virions carrying SIVsmm Envs
from a CCR5 wild-type animal (FFv) and a CCR5-null animal (FNp). Three days later, infection
was measured based on RLU (mean ± SD) in cell lysates. (B) Growth curves from infection of
primary SM PBMC (FAk: W/W SM; FAz: ∆2/∆2 SM). Cells were stimulated for 3 days with
PHA, then pretreated for one hour with or without maraviroc (15 uM), followed by infection with
two different SIVsmm primary isolates (M923 and M951) in the continued presence or absence
of maraviroc. SIV Gag p27 antigen levels in viral supernatants were measured by ELISA.
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Discussion
We unexpectedly found that 8% of sooty mangabeys in a large US captive
population lack functional CCR5 due to the high prevalence (29%) of mutations in the
CCR5 gene that abrogate cell surface expression and SIV coreceptor function. Despite
their CCR5-null status, homozygous mutant animals are susceptible to natural as well as
experimental SIVsmm infection and display viral loads only modestly lower than CCR5
wild-type animals. In vitro, SIVsmm enters primary SM lymphocytes independently of
CCR5, and Envs from both wild type and CCR5-null infected animals use several
alternative coreceptors in addition to CCR5, but do not use CXCR4. These data indicate
that both CCR5 and alternative coreceptor pathways mediate cell entry and robust viral
replication in vivo. The recognition that both CCR5-dependent and independent
pathways are used in the SM natural host has significant implications for understanding
viral tropism in vivo and CD4+ T cell subset targeting that may regulate the outcome of
natural host infection, and raises important questions about entry coreceptor use in
pathogenic non-human primate models of AIDS. This finding also explains the
previously obscure reason for widespread and efficient use of alternative coreceptors
among the SIVmac/smm family of viruses. Finally, it provides a third example of
convergent evolution resulting in disruption of CCR5 function among primates, with
consequences for virus-host interactions in SM that differ from both humans homozygous
for CCR5∆32 and red capped mangabeys homozygous for CCR5∆24.
From the original descriptions of alternative coreceptor use by SIVmac/smm
viruses, and subsequently by other SIV strains, the reason for conserved use of these
pathways has remained elusive (1, 18, 21). It has been repeatedly shown that various SIV
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isolates can infect primary human ∆32 homozygous PBMC independent of both CCR5
and CXCR4, indicating that alternative coreceptors are expressed in a manner that
supports infection in primary lymphocytes ex vivo, at least in cells of human origin (13,
15, 23, 39, 49, 76). Our data show for the first time that the alternative coreceptors are
used by SIVsmm in primary simian T cells ex vivo and, more importantly, in vivo in the
natural host from which the SIVmac/smm family derived. Several important questions
are raised by this finding: (1) are alternative pathways also operative in SM with wildtype CCR5 expression, or are they only relevant if CCR5 is absent; (2) what essential
role or selective advantage do they provide SIVsmm in SM infection in vivo that has led
to conservation of alternative coreceptor entry pathway use; (3) does alternative
coreceptor use define a novel population of CCR5-negative target cells that contributes to
the ability of host and virus to coexist without disease, and; (4) what role do alternative
pathways play in infection of macaques, the nonhuman primate model used to study
AIDS.
Prior to this confirmation that alternative pathways are used in vivo, it seemed
plausible that alternative coreceptor use by SIVsmm/mac was an in vitro epiphenomenon
of little biological significance. Recognizing that they are operative in vivo, it seems
more likely that conservation of their use among SIV isolates reflects some role that, if
not completely essential, offers a selective advantage for the virus. Comparison of viral
load data among the genotype groups showed robust replication in the absence of CCR5,
but a step-wise increase associated with the presence of one or two functional CCR5
alleles, and ex vivo blocking studies with maraviroc confirmed that both wild-type and
CCR5-null primary PBMC possess efficient CCR5-independent entry pathways. On one
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hand, if the relevant coreceptor(s) are expressed only on cells that also express CCR5, the
use of multiple pathways in vivo might be an example of functional redundancy acquired
by SIV, reminiscent in part of the functional redundancy of the chemokine/chemokine
receptor system. On the other hand, if CCR5 and alternative pathways are expressed on
distinct or only partially overlapping CD4+ T cell subsets, the 0.5 log10 VL difference
between ∆/∆ and W/W animals may also be consistent with separate components of
plasma viremia supported by CCR5 and non-CCR5 pathways (and an intermediate genedosage effect in the presence of one CCR5 allele). It is notable that the degree of
depletion in SM gut CD4+ T cells exceeds the proportion that express detectable CCR5
(28), and it will be important to determine if this is due to infection and targeting of
CCR5-negative cells in wild-type animals mediated by other coreceptors.
As to why alternative coreceptor use is conserved among SIVsmm and related
strains, it seems unlikely to result from the 8% prevalence of CCR5-null animals in SM,
and more likely reflects a unique role that provides an advantage over CCR5 alone in
transmission, establishment of reservoirs or other aspects of infection. Sooty mangabeys
overall express very low levels of CCR5 on CD4+ T cells, which has been proposed as an
evolutionary adaptive response to “protect” critical target cells and minimize
pathogenesis (52, 53). If so, acquisition of alternative coreceptor use by the virus may
have reflected a “counter-measure” to maximize replication capacity, although doing so
in a manner that still retains the nonpathogenic nature of infection. Thus, the use of
alternative entry pathways in vivo might enable infection of a novel CCR5-negative target
cell population that is more expendable than CCR5+ cells, allowing the virus to replicate
efficiently without causing disease in the face of extremely restricted CCR5 expression.
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It will therefore be important to define the distribution of cells infected in animals with
and without functional CCR5.
An important question raised by these SM findings is whether alternative
coreceptors are utilized in pathogenic infection of macaques, which is widely used to
model human AIDS. While CCR5 clearly plays a principal role as evidenced by
substantial albeit variable viral suppression by CCR5 antagonists (74, 75), levels of
CD4+ T cell infection in rhesus macaques can also substantially exceed the proportion of
cells that express detectable CCR5 (45). While it is possible that infection of apparently
CCR5-negative targets reflects entry mediated by CCR5 at levels below the threshold
detectable by FACS, our findings revive the question of whether it may be mediated by
additional entry pathways. Few studies have attempted to address alternative coreceptor
use in vivo. One report showed that mutations that abrogated GPR15 use by SIVmac had
little effect on replication or pathogenesis in rhesus macaques (57). Similarly, when
pigtail macaques (Macaca nemestrina) were infected with SIVmne (also derived from
SIVsmm), serial isolates exhibited decreasing ability to use alternative entry pathways
when assayed in vitro (23). On the other hand, in cynomolgus macaques (Macaca
fascicularis) infected with SIVsmm, animals with progressive disease showed retention
or broadening of alternative coreceptor use while those without disease progression
showed narrowing of alternative coreceptor use (39). Thus, it remains to be determined
whether alternative pathways support entry in particular subsets of CD4+ T cells in the
macaque model in vivo. Of note, emergence of CXCR4 use is common in HIV-1
infection of humans but exceedingly infrequent in macaques infected with SIVmac.
HIV-1 rarely uses alternative coreceptors efficiently and evolution to CXCR4 use by
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HIV-1 is believed to result, in part, from loss of CCR5+ target cells in late stage disease.
Thus, the availability of efficient alternative entry pathways may be one reason that SIV
rarely evolves to use CXCR4.
The SIVsmm Envs examined here use GPR15 and CXCR6 for entry quite
efficiently in vitro, and use GPR1 somewhat less efficiently. This result is concordant
with coreceptor use patterns of multiple other SIV isolates [22,23,30]. In human blood
cells, CXCR6 is highly expressed on CD4+ and CD8+ memory but not naïve T cells, and
on gamma-delta T and to a lesser extent NK cells (71), although others have reported
expression by CD4+ naïve T cells as well (66). Interestingly, CXCR6 expression is
regulated by T cell activation in a pattern that is tightly linked with CCR5 expression in
response to some stimuli, but markedly different in response to others (71). GPR15 is
also expressed on lymphoid and myeloid cells but with less information about specific
distribution patterns (18, 19, 21). Of note, both CXCR6 and GPR15 are also highly
expressed in intestinal tissues (18, 42), raising the question of whether alternative
coreceptor use may be involved in mucosal events that play a central role in infection.
Thus, CXCR6 and GPR15 are particularly likely candidates for mediating SM infection
independent of CCR5, and further studies are required to determine which one or ones
are responsible for entry into primary SM PBMC ex vivo and infection in vivo.
One of the most important priorities in HIV/AIDS research at present is
understanding why infected natural hosts remain healthy while rhesus macaques infected
with SIV, humans infected with HIV-1 or HIV-2, and chimpanzees infected with SIVcpz
develop AIDS. Many features are shared by non-pathogenic natural host and pathogenic
non-natural host infection including sustained high level viremia, vigorous immune
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activation during acute infection, and extensive depletion of gut mucosal CD4+ T cells.
In pathogenic infections it is believed that in addition to infection and loss of short-lived
T effector and T effector memory cells, damage to long-lived CD4+ Tcm populations that
impairs the capacity to maintain immune cell homeostasis is a critical factor in
progressive immunodeficiency (29, 48, 56). CCR5 levels are profoundly lower on SM
CD4+ T cells compared with RM and humans, which may restrict the target cells
available for infection in vivo (52, 53). More recently it has been found that CD4+ Tcm
in SM have particularly impaired CCR5 expression upon activation, and this corresponds
with markedly lower levels of cell-associated infection in Tcm compared with Tem cells
in SM, whereas both populations are similarly infected in RM (50). Thus, in addition to
the role of CCR5, it will be important to define the distribution and use of other
coreceptors by SIVsmm in its natural host as well as in pathogenic rhesus macaque
infection. Another prominent difference between pathogenic infection and
nonpathogenic natural host infection is the presence of sustained high level generalized
immune activation in rhesus and humans, whereas acute infection in natural hosts is
associated with transient immune activation that rapidly resolves (7, 20, 22, 27, 40, 68).
Sustained immune activation during chronic infection may be an additional factor driving
T cell turnover and depletion. A principal mechanism driving chronic immune activation
is believed to be translocation of microbial products due to disruption of gut mucosal
barrier integrity that occurs early in infection (9). However, gut mucosal lymphocyte
infection and CD4+ T cell depletion occurs in natural host as well as pathogenic host
infection (28, 54). One potentially critical difference is the loss in human and rhesus
macaque infection, but preservation in natural hosts, of mucosal CD4 Th17 cells, which
80

play a critical role in gut mucosal immune defense (8, 12, 22, 58). Why gut Th17 CD4+
T cells are preserved in infected natural hosts but depleted in other hosts remains to be
determined, but the critical role of entry coreceptors in determining tropism and cell
subset infection in vivo suggest that both CCR5 and alternative coreceptor pathways must
be defined in order to understand the targeting versus protection of critical CD4+ cell
subsets.
In addition to the YNPRC and TNPRC SM colonies, we also found the ∆2 allele
in SM in the Tai forest of Cote d’Ivoire, confirming its presence not just in captive but
also in wild-living West African animals, albeit at a lower frequency. Sooty mangabeys
at YNPRC were derived from multiple sources and their history is not well documented
(5), so it is difficult to know for sure from what geographic regions in West Africa these
animals descended. Of note, the ∆2 allele was not described in earlier studies that
reported the ∆24 allele in SM from West Africa and the YNPRC colony (14, 51).
However, CCR5 alleles in those studies were screened by PCR amplicon size, which
could discriminate a 24 bp size difference but is unlikely to distinguish a 2 bp difference
between the wild type and ∆2 alleles.
The identification here of SM CCR5∆2 brings to three the number of primates
known to have a high prevalence of defective CCR5 alleles. Interestingly, each of the
three examples of populations with homozygous mutant CCR5 individuals shows distinct
patterns of host/virus interactions. For HIV-1 in humans, which have the lowest
prevalence of defective CCR5 genes (~1% among Caucasians), CCR5 use is a stringent
requirement for establishment of new infections, and its absence in the host provides
almost complete protection from infection even though late-stage variants can use
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CXCR4 and, occasionally, other coreceptors. In RCM, which have the highest
prevalence of CCR5-null individuals (≥70%), SIVrcm has adapted to use CCR2b as a
coreceptor and lost the ability to use CCR5 (14). SIVsmm infection in SM, which have
an intermediate prevalence of CCR5-null individuals (8% in this population),
demonstrate an intermediate relationship, in which alternative coreceptors efficiently
mediate both natural and experimental infection in the absence of CCR5, but CCR5 use
by the virus is retained, perhaps because both CCR5 and alternative pathways together
maximize replication in the majority of animals, while the non-CCR5 pathways are
required in the CCR5-null animals.
It is somewhat unexpected that SIVsmm does not use CCR2b, which is the route
of entry taken by SIVrcm in the absence of CCR5. SM and RCM are closely related and
sometimes considered sub-species within the same species (14, 26). The presence of the
same CCR5∆24 allele in RCM and SM has been interpreted as indicating an origin prior
to separation of these populations, although it is uncertain if the remarkably high
frequency CCR5∆24 in the RCM population reflects selective pressure exerted by an
environmental or infectious cause, or founder effect (14). Another question raised by our
results is whether the SM CCR5∆2 and the SM/RCM CCR5∆24 emerged independently,
resulting in deletions in the same region due to multiple nucleotide repeats enabling
recombination, or given the overlapping sites whether ∆2 emerged first and additional
events led to ∆24. Since ∆2 is not expressed, it is unlikely that further deletions would
lead to any additional selective advantage, and two separate recombination deletion
events in the same region of the same gene seem more probable.
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What selective pressures might have led to three independent primate CCR5
deletion alleles is uncertain. CCR5∆32 has been present in the human population for at
least 3000 years (34), far longer than HIV-1, and despite considerable speculation on
infectious or other pressures, both what factors fueled its emergence and when it occurred
remain enigmatic (30). In contrast, SIV has been endemic in the SM and RCM
populations for much longer, although whether its entry predated separation of the
populations is uncertain (26). The CCR5 mutation is currently not essential for
protection from SIV-induced pathogenesis, but it is plausible that each of the mutations
result from ancestral evolutionary pressure by pathogenic SIV infection. For SM, genetic
abrogation of CCR5 expression may have been an additional, complementary response to
control pathogenesis along with phenotypic CCR5 downregulation (50, 52). If so, in both
SM and RCM the virus then acquired mechanisms to circumvent the restriction, by
expanding coreceptor use for SIVsmm or switching for SIVrcm, yet the hosts then
acquired other additional mechanisms to avoid pathogenesis. Alternatively, it may be
that all three CCR5 mutations, human, SM and RCM, reflect evolutionary adaptation to
some other as-yet unidentified infectious or other environmental factor acting similarly
on all three types of primates. Nevertheless, whatever its origin and frequency, the SM
CCR5∆2 mutation here expands the pathways known to support infection in this
important natural host model, the identity, distribution and utilization of which must be
taken into account in understanding SM infection in vivo, and the similarities or
differences from RM infection that determine outcome from infection.

83

Supplemental Figures

Figure 2-S1. Analysis of sooty mangabey CCR5 genotypes.
(A) Genomic DNA was analyzed by PCR in two separate reactions that contained primers
specific for the wild-type or ∆2 CCR5 alleles. (B) Genomic DNA was amplified with CCR5specific primers that generate an amplicon of 227-229 bp for the ∆2 and wild-type alleles, or 205
bp for the ∆24 allele. Note that animals 1-6 in panel A do not correspond to numbers in panel B.
(C) Direct sequence validation of genotypes is shown in representative chromatographs of
animals from each of the 5 genotypes identified in this analysis: W/W, W/∆2; ∆2/∆2; W/∆24 and
∆2/∆24. Red arrow indicates the site of ∆2 or ∆24 frameshifts and blue arrow indicates a single
nucleotide polymorphism (T in wild-type; G in ∆2 and ∆24 alleles) that results in a coding change
(Leu in wild-type; Val in ∆2 and ∆24 alleles).
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Figure 2-S2. Lack of dominant negative effect of mutant CCR5 alleles.
293T cells were transfected with wild-type smCCR5 plasmid (1 ug) along with plasmids
encoding CCR5∆2, CCR5∆24 or pcDNA3 (1 ug of each plasmid). CCR5 expression was
determined by staining with mAb 3A9 and FACS analysis.
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Figure 2-S3. Blood CD4+ T cell levels in infected sooty mangabeys between genotype
groups.
(A) CD4+ T cell counts (cells/ul; mean ± SEM; left) and (B) CD4+ T cell as a percentage of
CD3+ cells (mean ± SEM; right) from infected animals in the wild-type (n=60), heterozygote
(n=49) and homozygous mutant (n=7) genotype groups. CD4+ T cells are not significantly
different between groups (p=ns for absolute cell counts by Kruskal-Wallis test; p=ns for %CD4+
cells by ANOVA).
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Figure 2-S4. Relative use of alternative coreceptors compared with CCR5.
Representative experiment in which CCR5 and alternative coreceptors were tested in parallel with
a subset of SIVsmm Env pseudotype viruses.
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CHAPTER III

CXCR6 AND GPR15 EXPRESSION:
PRELIMINARY EXAMINATION ON HUMAN PBMC SUBSETS
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Abstract
Understanding the virus/host relationship in natural hosts will enable better understanding
of pathogenic HIV infection of humans. SIV infection of sooty mangabey (SM) natural
hosts does not cause disease, despite robust virus replication. SIV uses CCR5 for entry
into target cells, but SM and other natural hosts express very low CCR5 levels on CD4+
T cells. I have shown that SIVsmm can utilize non-CCR5 entry pathways in the SM
natural host, in vivo. Based on in vitro infection assays, we hypothesized that CXCR6
and GPR15 serve as alternative SIV entry coreceptors in vivo. Ultimately, we wish to
determine whether alternative coreceptor expression patterns in SM effects target cell
tropism in these animals. Here, I sought to examine the expression patterns of CXCR6
and GPR15, in addition to CCR5 on primary human cells using multi-color flow
cytometry. I show that on human CD4 T cells, CXCR6 and GPR15 are: i) predominantly
expressed on memory cell subsets, ii) detected to some extent on effector cells, and iii)
present at extremely low levels on naïve cells. On lymphocytes, the percentage of cells
expressing CCR5 and CXCR6 increased upon CD3/CD28-stimuation, whereas the
percentage of GPR15-expressing cells did not change. A large percentage of resting and
stimulated CD4+ memory cells expressed CCR5 alone, while a similar percentage of
CD4+ memory cells co-expressed CCR5 and CXCR6 upon stimulation. Notably, coexpression of CXCR6 and GPR15 was extremely rare. This work serves as a framework
for future studies comparing cell subset specific expression patterns in SM and nonnatural hosts.
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Introduction
Several chemokine receptors and chemokine receptor-like orphan receptors serve
as entry coreceptors, along with CD4, for HIV/SIV. In vivo, CCR5 and CXCR4 are the
primary entry coreceptors used by HIV while CCR5 was long thought to serve as the
main coreceptor for SIV (1-4, 6, 7, 16). Numerous studies report that SIV has a broad
coreceptor range in vitro, and has been shown to utilize CXCR6 (Bonzo/STRL33),
GPR15 (BOB), GPR1, ChemR23 and APJ for entry (8, 9, 19-21, 25). However, SIV use
of alternative coreceptors was considered an in vitro phenomenon, with the notion that
CCR5 served as the exclusive entry coreceptor, in vivo. My identification of SIVsmminfected CCR5-null SM indicated otherwise. This observation indicates that SIVsmm
can utilize alternative coreceptors for transmission and replication in CCR5-null SM, in
vivo (22), and that the expression and distribution of alternative coreceptors may define
novel cell subsets that are more expendable allowing for high virus replication without
causing disease.
This finding raises many questions: i) which alternative coreceptors mediate SIV
entry in vivo, ii) what primary cell subsets express alternative coreceptors, iii) is
alternative coreceptor use by SIV seen in other natural host species besides SM, and iv)
does alternative coreceptor expression differ between natural hosts, that have presumably
evolved to avoid pathogenesis, and non-natural hosts, which have not? Based on in vitro
entry assays by myself and others, I hypothesize that CXCR6 and GPR15 are likely entry
coreceptors used by SIVsmm (8, 22). Many of these studies used human-derived
alternative coreceptors, however, a recent study from our lab confirmed that SM-derived
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CXCR6 and GPR15 support efficient SIV entry in a transfection-based assay system
suggesting that these alternative coreceptors may support SIVsmm entry in vivo (10).
Since a SM-specific anti-CXCR6 antibody is not available, we set out to first
define CXCR6 and GPR15 expression profiles on human primary cells. CXCR6 is the
receptor for CXCL16 (17), while GPR15 is an orphan receptor for which the natural
ligand is not yet known (13). Although, the expression profile of CXCR6 on human
primary cells has been reported, the findings are conflicting. One group reported that
CXCR6 expression is mainly detected on naïve CD4+ T cells as well as natural killer
(NK) cells and B lymphocytes (25), while another group reported CXCR6 expression is
restricted to memory subsets of CD4+ and CD8+ T cells (26). We attempted to clarify
CXCR6 expression profiles on resting and stimulated human PBMC subsets. The other
coreceptor of interest is GPR15; although not much expression data is available, GPR15
mRNA has been detected in human alveolar macrophages and CD4 lymphocytes as well
as in activated RM PBMC (5, 11). Additionally, a recent study revealed low level
GPR15 expression on resting and stimulated human PBMC (14).
The current study will allow us to compare CXCR6 and GPR15 expression
patterns, in addition to CCR5, on human CD4+ T cell subsets. This work serves as a
framework for future studies comparing CXCR6 and GPR15 expression patterns in SM,
which we hypothesize evolved to restrict expression to dispensible cell types. In addition
to implications for SIV, understanding alternative coreceptor expression patterns on
human cells is important because i) while rare, HIV alternative coreceptor use has been
described, and ii) with CCR5 knock-out efforts, alternative coreceptor use might become
an issue.
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Materials and Methods
Isolation and stimulation of primary human cells
Fresh human PBMC were obtained from normal donors from the University of
Pennsylvania Immunology core. Human PBMC from a single donor were divided into
two equal groups. Ten million cells were rested overnight at 37°C, and the remaining
cells were stimulated for three days in the presence of plate-bound CD3/CD28 antibodies.
Three days post-antibody stimulation, recombinant IL-2 was added to cells for four
additional days in the continued presence of CD3/CD28 antibodies.

Staining procedure
Prior to antibody stimulation, cells were stained with Live/Dead Dye according to the
manufacturer’s instructions. On appropriate days, PBMC were stained with antibodies
for the following: (i) lineage markers - CD3 (APC-Cy7), CD4 (FITC), CD8 (PE-Texas
Red) and CD14, (ii) memory markers - CD27 (PE-Cy7) and CD45RO (PE-Cy5), and (iii)
coreceptors - CCR5 (PE), CXCR6 (APC) and GPR15 (PerCP-Cy5.5). Cells were stained
at 4ºC in the dark for 30 minutes. After incubation, cells were washed with 1ml FACS
buffer (PBS + 1% FBS + 0.1% sodium azide) three times. Cells were fixed with 0.4ml
2% paraformaldehyde in FACS buffer.

Analysis
Approximately, 2 x 105 cells were acquired on an LSR-II, and data was analyzed using
FloJo software. As shown in Figure 3-1, cells were gated based on characteristic light
scatter properties followed by the selection of live cells (Figure 3-1; A,B). Cells were
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then separated based on CD3 and CD14 expression (C), and CD3-positive cells were
divided based on expression of CD4 and CD8 (D). CD3+CD4+ cells were then divided
into naïve and memory cell subsets based on CD45RO and CD27 co-expression (E).
Lastly, coreceptor expression levels were measured on each CD4 T cell subset (naïve,
CD27+ memory, CD27- memory and effector cells).

Quantitative PCR – Coreceptor mRNA levels
Primary PBMC from SM were left unstimulated or cultured in the presence of
Concanavalin A and IL-2 for up to 5 days. CD4+ cells were sorted from PBMC at 0 and
120 hours post-stimulation using negative selection. Total RNA was isolated from
purified CD4) cells using the RNAeasy extraction kit (Qiagen) according to the
manufacturer’s instructions. Quantification of mRNA levels for all coreceptors tested
was performed by RT-PCR using the SYBR-Green assay. Levels of CCR5, CXCR6,
GPR15, GPR1 and APJ mRNA were normalized to the expression of the housekeeping
mRNA, GAPDH.
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Results
CXCR6 and GPR15 are detected on CD4+ and double negative (CD4-/CD8-) T
cells; CXCR6 are detected on CD8+ T cells
I aimed to define the expression profile of CXCR6 and GPR15 on human primary
cells; these receptors have been shown to support SIV entry in vitro. I first determined
the expression levels of CXCR6 and GPR15 on various T cell populations. For the sake
of comparison and since CCR5 expression levels are well established on human cells, we
also measured CCR5 expression on various T cell populations. On resting lymphocytes,
the average percentage of cells expressing CXCR6 was 1.3% on CD4+ and CD8+ T
cells, and 5.5% on DN T cells. On average, GPR15 expression was detected on 2.4%
CD4+ T cells and 12.2% DN T cells; GPR15 expression was extremely low to
undetectable on resting CD8+ T cells. The average percentage of resting cells expressing
CCR5 was 8.6% on CD4+ T cells, 22.3% on CD8+ T cells and 63.2% on DN T cells.
Flow plots from a representative donor are shown in Figure 3-2. In all, these data
demonstrate that CXCR6 and GPR15 expression is detected on a small percentage of
resting lymphocytes.
I next examined CXCR6 and GPR15 expression on CD3/CD28-stimulated cells
from matching donors. On stimulated lymphocytes, the average percentage of cells
expressing CXCR6 was 8.5% on CD4 T cells, 4.2% on CD8 T cells and 13.1% on DN T
cells. On average, GPR15 expression was detected on 5.1% CD4 T cells and 12.2% DN
T cells; GPR15 expression was also extremely low on stimulated CD8 T cells. The
average percentage of stimulated lymphocytes expressing CCR5 was 18.8% on CD4 T
cells, 13.3% on CD8 T cells and 33.9% on DN T cells. These results show that
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CD3/CD28-stimulation increased the percentage of cells expressing CXCR6 and GPR15,
as well as CCR5 (Figure 3-2). Percentages of CXCR6, GPR15 and CCR5 expression on
resting and stimulated cells from both donors are listed in Table 3-1.
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Figure 3-1. Gating strategy for analysis of coreceptor expression levels on total CD4 T cells
and CD4 T cell subsets.
Representative FACS plots showing the successive gating strategy used on unstimulated (rested)
human PBMC stained for lineage markers (CD3, CD4, CD8 and CD14), memory markers
(CD45RO and CD27), and coreceptors of interest (CCR5, CXCR6 and GPR15). Live cells were
separated using a Live/Dead stain. Gated populations (cells within pink gated region) from one
FACS plot are the total cells shown in the subsequent FACS plot. This gating strategy was used
to determine coreceptor expression on total CD4 T cells (plots A – D) and CD4 T cell subsets
(plots A – E). The percentage of cells in a particular gated area or quadrant are located at the top
right-hand corner of the plot.
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Figure 3-2. CCR5, CXCR6 and GPR15 expression levels on rested and stimulated human
CD4, CD8 and double negative (CD4-CD8-) T cells.
Resting (overnight incubation at 37°C) and stimulated (one week incubation: three days in the
presence of CD3/CD28 antibodies followed by four days in the presence of IL-2) human PBMC
were stained with lineage markers (CD3, CD4, CD8 and CD14), memory markers (CD45RO and
CD27), and coreceptors of interest (CCR5, CXCR6 and GPR15). The percentage of cells
expressing each coreceptor of interest on total A) CD4, B) CD8 and C) double negative (CD4/CD8-) T cells is displayed in each FACS plot. A combination of florescence minus one (FMO),
isotype-matched antibodies and staining with secondary antibody alone served as negative
controls (data not shown). Representative data set from one of two donors.
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Table 3-1. Percentage of CCR5, CXCR6 and GPR15 expression on resting and stimulated human
PBMC cell subsets
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CXCR6 and GPR15 are predominantly expressed on CD4+ memory cell subsets;
CXCR6 and GPR15 expression is extremely low on CD4+ naïve T cells
Since cells expressing CD4 are potential targets for HIV/SIV, we wanted to
determine the expression levels of CXCR6 and GPR15, in addition to CCR5, on CD4 T
cell subsets. CXCR6, GPR15 and CCR5 expression is extremely low (~1.0%) on naïve
CD4 T cells (CD45RO-/CD27+) on both resting and CD3/CD28-stimulated cells
(Figures 3-3 & 3-4). Similar to CCR5 expression, CXCR6 and GPR15 were both
detected primarily on CD45RO+/CD27+ memory cells (predominantly central memory
cells; Tcm), CD45RO+/CD27- memory cells (primarily effector memory cells; Tem) and
effector (CD45RO-/CD27-) cell subsets, although CXCR6 and GPR15 expression was
relatively lower than CCR5 expression on all subsets examined.
Both CXCR6 and CCR5 expression levels are higher on CD45RO+/CD27memory cells (primarily Tem) than CD45RO+/CD27+ memory cells (predominantly
Tcm), and expression of these coreceptors is upregulated upon CD3/CD28 antibody
stimulation. The percentage of CXCR6-expressing cells increased from an average of
1.3% to 10.0% on resting versus stimulated CD45RO+/CD27+ memory cells
(predominantly Tcm), respectively, while CCR5-expressing cells increased from an
average of 12.9% to 24.7%, respectively. The average percentage of CD45RO+/CD27+
cells expressing GPR15 modestly increased from 3.9% on resting cells to 6.5% on
stimulated cells. On CD45RO+/CD27- memory cells (mostly Tem), CD3/CD28stimulation increased CXCR6 and CCR5 expression. On average, the percentage of
CXCR6-expressing cells increased from 3.1% on resting cells to 35.8% on stimulated
cells, while the average percentage of CCR5-expressing cells increased from 34% to 60%
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on resting and stimulated cells, respectively. The average percentage of GPR15expressing cells increased from 5.2% on resting cells to 11.6% on stimulated cells.
However, increased GPR15 expression upon stimulation was not observed in both donors
examined. One donor did not show in increase in GPR15 expression on resting versus
stimulated CD45RO+/CD27- cells (6.3% to 5.7%, respectively), while the other donor
did (4.3% to 17.4%, respectively). Overall, these results suggest that CXCR6 and GPR15
are predominantly expressed on memory cell subsets (CD45RO+/CD27+ and
CD45RO+/CD27-) and are expressed at extremely low levels on naïve CD4 T cells. The
percentage of cell expressing CXCR6, GPR15 and CCR5 from various cell subsets are
displayed in Figures 3-3 and 3-4. In addition to CD3/CD28 antibody stimulation, cells
were also stimulated with phytohemagglutinin (PHA), which yielded similar results in
that most coreceptor expression was detected on memory cell subsets (Table 3-2).
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Figure 3-3. CCR5, CXCR6 and GPR15 expression levels on rested CD4 T cell subsets.
Resting human PBMC were stained as previously described in Figure 3-1. Total CD4 T cells
were divided into naïve, memory and effector cell subsets based on combinations of CD45RO
and CD27 co-expression (plot on far left). Arrows point from each quadrant to corresponding
FACS plot of coreceptor expression for that particular subsets. For each subset, the percentage of
cells expressing a particular coreceptor, CCR5 (left), CXCR6 (middle) and GPR15 (right), is
displayed in the FACS plot. Representative data set from one of two donors.
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Figure 3-4. CCR5, CXCR6 and GPR15 expression levels on CD3/CD28-stimulated CD4 T
cell subsets.
CD3/CD28-stimulated human PBMC were stained as previously described in Figure 3-1. Total
CD4 T cells were divided into naïve, memory and effector cell subsets based on combinations of
CD45RO and CD27 co-expression (plot on far left). Arrows point from each quadrant to
corresponding FACS plot of coreceptor expression for that particular subsets. For each subset,
the percentage of cells expressing a particular coreceptor, CCR5 (left), CXCR6 (middle) and
GPR15 (right), is displayed in the FACS plot. Representative data set from one of two donors.
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Table 3-2. Percentage of CCR5, CXCR6 and GPR15 expression on resting and stimulated (PHA
and CD3/CD28) CD4 T cell subsets.
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CXCR6/CCR5 co-expression increases dramatically upon CD3/CD28-stimulation;
CXCR6/GPR15 co-expression is rare on resting and stimulated CD4+ T cells
Although HIV use of alternative coreceptors is rare in vivo, we wanted to
determine if CXCR6 and GPR15 are co-expressed on human cells expressing CCR5.
Furthermore, it will be interesting to ultimately compare and contrast co-expression
profiles of CXCR6, GPR15 and CCR5 between natural and non-natural hosts. We
hypothesize that alternative coreceptor expression profiles on natural host primary cells
may reveal novel target cell subsets that lack CCR5 yet express CXCR6 and/or GPR15,
which may support viral entry and replication, in vivo. Here we are studying human
cells, which have not evolved under such pressure so CXCR6 and GPR15 may be
expressed predominantly on CCR5-expressing cells.
We examined the co-expression of CXCR6, GPR15 and CCR5 on CD4+ memory
subsets (CD45RO+/CD27+ and CD45RO+/CD27-) because memory subsets expressed
most robust levels of each coreceptor alone (and effector cells were rare). We first
determined the percentage of cells expressing CXCR6, GPR15 and CCR5 alone on
resting and CD3/CD28-stimulated cells. On resting CD45RO+/CD27- memory cells,
roughly 30% of cells expressed CCR5 alone, ~1% cells expressed only CXCR6 and 2%
of cells expressed GPR15 alone. Notably, the percentage of CD3/CD28-stimulated cells
expressing CCR5 or GPR15 were similar to expression levels seen on resting cells while
CXCR6 expression increased to roughly 3% on stimulated CD45RO+/CD27- memory
cells (Figure 3-5A).
The percentage of cells expressing at least one coreceptor substantially increased
upon CD3/CD28-stimulation. This increase in coreceptor expression can be appreciated
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by a decrease in the total percentage of coreceptor-negative CD45RO+/CD27- memory
cells (primarily effector memory cells) upon stimulation. When examining coreceptor
co-expression on this subset, the most dramatic effect was in cells expressing both
CXCR6 and CCR5. CXCR6/CCR5+ cells increased substantially upon stimulation from
2.5% on resting cells to ~30% on stimulated cells. Less than 5% of resting and
stimulated CD45RO+/CD27- memory cells were positive for both GPR15 and CCR5,
with a modest increase in co-expression of these two coreceptors on stimulated cells.
Surprisingly, CXCR6 and GPR15 co-expression was not detected on resting
CD45RO+/CD27- memory cells, and only ~1% of stimulated cells were positive for
these receptors. Additionally, on average, 5% of stimulated CD45RO+/CD27- memory
cells express all three coreceptors, which is considerably higher than the percentage of
triple positive resting cells (Figure 3-5A). Thus, CD3/CD28 stimulation leads to a large
increase in CD45RO+/CD27- (Tem) cells co-expressing CXCR6 and CCR5.
Examination of coreceptor expression profiles on CD45RO+/CD27+ memory
cells, reflecting predominantly Tcm cells, revealed similar co-expression trends as seen
on CD45RO+/CD27- memory cells (primarily Tem cells). Approximately, 85% of
resting CD45RO+/CD27+ memory cells lacked CXCR6, GPR15 and CCR5, while the
largest proportion of coreceptor-expressing cells were singly positive for CCR5 and
GPR15 (Figure 3-5B). Stimulation led to upregulation of coreceptor expression on
CD45RO+/CD27+ memory cells, however the overall percentage of CXCR6, GPR15 or
CCR5-expressing CD45RO+/CD27+ memory cells was considerably lower than the
percentage of CD45RO+/CD27- memory cells expressing these coreceptors. As seen in
CD45RO+/CD27- memory cells, a large proportion of stimulated CD45RO+/CD27+
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memory cells expressed CCR5 alone or CXCR6 in combination with CCR5. Of note,
CXCR6 and GPR15 co-expression was not detected on resting or stimulated
CD45RO+/CD27+ memory cells, and less than 1% of these cells expressed all three
coreceptors (Figure 3-5B).

113

-.&

Tem
!"#$"%&

'()*+,$"%&

70
60
50
40
30
20
10

Rested
Stimulated

5

!"#$%&
'()*+&

0
CCR5!

−!

+!

−!

−!

+!

+!

−!

+!

CXCR6!

−!

−!

+!

−!

+!

−!

+!

+!

GPR15!

−!

−!

−!

+!

−!

+!

+!

+!

Tcm/Ttm

/.&

90

Rested
Stimulated

70
50
30
20
10

!"#$,&
'(-*+&

0
CCR5!

−!

+!

−!

−!

+!

+!

−!

+!

CXCR6!

−!

−!

+!

−!

+!

−!

+!

+!

GPR15!

−!

−!

−!

+!

−!

+!

+!

+!

Figure 3-5. Co-expression of CCR5, CXCR6 and GPR15 on resting and stimulated CD4 T
cell subsets.
Resting (blue columns) and stimulated (CD3/CD28; red columns) human PBMC were stained
and analyzed, gating on CD3+, CD4+ CD45RO+ cells as previously described in Figure 3-1. Coexpression of CCR5, CXCR6 and GPR15 on A) CD27- (primarily Tem) and B) CD27+
(primarily Tcm) subsets was determined using Boolean gating. For each cell subset, the mean
percentage of coreceptor expression for all single and multiple combinations are shown (mean +
SEM; n=2).
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CXCR6 and GPR15 mRNA levels are relatively higher than CCR5 mRNA levels in
resting and stimulated SM CD4 cells
My work (Chapter 2) showed CCR5-independent SIVsmm infection in vivo and
in primary SM cells ex vivo, and that human-derived CXCR6 and GPR15 support robust
SIVsmm entry in vitro. A follow-up study from our lab showed that SM-derived CXCR6
and GPR15 support SIV entry in vitro (10). We hypothesize that these alternative
coreceptors are likely used in vivo. Antibodies to SM-CXCR6 are not currently
available, therefore we sought to determine the mRNA levels of these alternative
coreceptors on SM CD4+ cells using quantitative PCR. As shown in Figure 3-6,
CXCR6 and GPR15 mRNA levels are relatively high compared to CCR5, GPR1 and APJ
mRNA levels in unstimulated SM CD4+ cells. Of note, GPR1 and APJ are additional
alternative coreceptors that have been shown to mediate SIV entry in vitro. Furthermore,
a decrease in CCR5, GPR1 and APJ mRNA levels occurred in SM CD4+ cells stimulated
with concanavalin A, while the average mRNA levels of CXCR6 and GPR15 remained
the same. However, there is considerable variation in CXCR6 and GPR15 mRNA levels
between individual animals tested (Figure 3-6). Although mRNA levels do not directly
predict protein expression levels, these results in SM primary cells are consistent with our
hypothesis that CXCR6 and GPR15 may act as entry coreceptors in vivo in addition to
CCR5.
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Figure 3-6. Coreceptor mRNA levels in resting and stimulated sooty mangabey CD4+ cells.
Purified SM CD4+ cells were left untreated (resting) or stimulated with concanavalin A for five
days at 37°C. Coreceptor-specific primers were used to amplify cDNA derived from each cell
source to determine mRNA levels using quantitative PCR. Plasmid DNA containing each
coreceptor of interest was used to create a standard curve. GAPDH was used as an internal
control and coreceptor copy numbers were plotted relative to GAPDH mRNA levels. (Data from
N. Francella, unpublished)
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Discussion
Chemokine receptors other than CCR5 and CXCR4 can support SIV, and to a
lesser extent HIV, entry in vitro. SIV use of alternative coreceptors such as CCR2,
CCR4, CCR8, CX3CR1, APJ, GPR1, GPR15 and CXCR6 has been described
extensively (5, 8, 19, 23, 24), and most SIV strains can propagate in human T cell lines
that do not express CCR5 as well as in CCR5-null (∆32 homozygous) primary human
lymphocytes (2, 12). Since CXCR4 use by SIV is extremely rare, these data suggest that
non-CCR5 pathways can mediate SIV infection ex vivo. HIV primary isolates have been
shown to use alternative coreceptors for entry, although in most cases HIV use is far less
robust than SIV use (25). Much of the evidence on alternative coreceptor use came from
in vitro infection assays, and little is known about alternative coreceptor use or
expression patterns in vivo.
Our lab recently published the first piece of conclusive evidence that non-CCR5
pathways support robust SIV transmission and replication in vivo. I identified a novel
mutant SM-CCR5 allele (∆2), and genotyped a large cohort of SM to determine the
prevalence of mutant SM-CCR5 alleles (∆2 and ∆24), which led to the identification of a
group of CCR5-null animals. Surprisingly, half of the CCR5-null SM were naturally
infected with SIVsmm. This observation revealed that alternative coreceptors support
SIV transmission and replication in vivo, indicating that these receptors must be
expressed on SM CD4+ cells. I then showed that CXCR6 and GPR15 (of human origin)
serve as efficient SIVsmm entry pathways in vitro (22). A follow-up study from our lab
showed that SM-derived CXCR6 and GPR15 supported SIV entry as efficiently as CCR5
in a pseudotype infection assay (10). Based on these findings, we sought to study the
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expression profiles of CXCR6 and GPR15 on human and SM primary cells. I first set out
to examine the expression profile of CXCR6, GPR15 and CCR5 on various human cell
populations since there is no anti-CXCR6 antibody currently available that cross-reacts
with the SM molecule.
In human primary cells, I found CXCR6 and CCR5 expression detected on CD4+,
CD8+ and DN T cells, whereas GPR15 expression was detected on CD4+ and DN T
cells, but not on CD8+ T cells. Since CD4+ T cells are the target cells of HIV/SIV, we
sought to investigate the expression patterns of CXCR6 and GPR15, with that of CCR5,
on resting and stimulated CD4+ T cell subsets. Functional CD4+ T cell subsets
(naïve/memory/effectors) can be distinguished based on the expression of a number of
surface antigens such as CD45RA, CD45RO, CD27, CD62L and CCR7. In our study,
specific combinations of CD45RO and CD27 expression were used to define naïve,
memory and effector cell subsets. Of note, CD27+ memory cells (CD45RO+) are
comprised primarily of central memory cells while CD27- memory cells are
predominantly made up of effector memory cells.
Chemokine receptor expression patterns are important for determining viral
tropism. It is well established that CCR5 is restricted to memory and effector subsets on
CD4+ T cells, which is consistent with depletion of CD4+ memory cells in mucosal
tissues during acute SIV infection (18). It is likely that memory CD4+ T cells are
preferentially targeted by HIV because they express high CCR5 levels and exist in a
relatively activated state. Here we found that like CCR5, CXCR6 and GPR15 are
predominantly expressed on memory (CD27+ and CD27-) CD4+ T cell subsets, and are
expressed at extremely low levels on naïve CD4+ T cells. Prior studies, reporting
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CXCR6 expression patterns were discordant; one group described CXCR6 expression on
naïve CD4+ T cells, B cells and a subset of natural killer (NK) cells, while another group
showed CXCR6 expression is predominantly restricted to memory CD4+ and CD8+ T
cells (25, 26). Our finding that CXCR6 expression is highly restricted to memory CD4+
T cells is consistent with the latter study.
Meanwhile, the regulation of CXCR6 has also been examined (15, 26). One
study showed that the expression pattern and regulation of CXCR6 paralleled that of
CCR5, and inversely correlated with that of CXCR4 (26). Our results corroborate these
findings in regard to CXCR6/CCR5 co-expression. Like CCR5, CXCR6 expression is
highly restricted to memory CD4+ T cells and is up-regulated upon CD3/CD28
stimulation. Interestingly, when examining co-expression of CXCR6, GPR15 and CCR5
on CD27+ and CD27- memory CD4+ T cells, the percentage of cells expressing both
CXCR6 and CCR5 increased significantly upon stimulation. Notably, a small percentage
of cells expressed CXCR6 alone while the majority of CXCR6+ cells were also CCR5+;
CXCR6 and GPR15 co-expression was extremely rare.
The CD3/CD28 antibody stimulation method (plate-bound) used in this study
resulted in the up-regulation of CXCR6, GPR15 and CCR5. An examination of the
percentage of cells in each CD4 T cell subset revealed that while the percentage of
CD27+ memory cells (mostly Tcm) increased upon stimulation (38.1% of resting cells;
53.6% of stimulated cells), a substantial proportion of cells sustained the naïve phenotype
(41%) after stimulation. Although our findings show a considerable increase in CXCR6
and CCR5 expression using the CD3/CD28 plate-bound method, it is likely that upregulation of coreceptor expression may have increased more dramatically if the cells
119

were more uniformly stimulated, such as through the use of CD3/CD28 beads. Notably,
PHA-administration provided a more homogenous stimulation resulting in 7.2% naïve
CD4 T cells compared to 41% naïve CD4 T cells after CD3/CD28 (plate-bound)
stimulation. However, PHA stimulation did not induce a substantial increase in
coreceptor expression (Tables 3-1 and 3-2). This finding indicates that coreceptor
regulation differs under different stimulation conditions.
Although alternative coreceptor use by HIV is rare, a recent study identified a
transmitted/founder virus that efficiently infected cell lines over-expressing GPR15,
FPRL and APJ (14). Based on our GPR15 expression patterns on human primary cells,
one could speculate that this particular HIV isolate would exhibit similar viral tropism as
an R5-tropic virus since CCR5 and GPR15 were predominantly expressed on human
memory CD4+ T cells.
Nevertheless, expression profiles on primary human cells may not be indicative of
expression on primary NHP cells, which emphasizes the importance of defining CXCR6
and GPR15 expression profiles, relative to that of CCR5, on primary SM cells. Using
quantitative PCR, we detected CXCR6 and GPR15 mRNA levels in SM CD4+ cells.
Notably, CXCR6 and GPR15 mRNA levels were relatively higher than CCR5 mRNA
levels in these cells. Despite this promising result, we do not know how mRNA levels
correspond to protein expression levels. However, detection of CXCR6 and GPR15 on
SM CD4+ cells is consistent with our hypothesis that alternative entry pathways mediate
SIV infection in CCR5-null SM.
These results provide a background for further studies in NHP. Once a SM antiCXCR6 antibody is available, it will be important to explore CXCR6 and GPR15
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expression profiles on primary SM cells. Ultimately, it would be interesting to determine
if alternative coreceptor expression profiles differ between natural and non-natural hosts,
which may reveal novel target cell subsets that contribute to the non-pathogenic nature of
SIV in infected natural hosts.
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DISCUSSION & CONCLUSIONS

125

Presently, one of the most important priorities in HIV/AIDS research is
understanding why infected natural hosts remain healthy while SIV-infected RM, HIVinfected humans and SIVcpz-infected chimpanzees develop AIDS. Although enormous
progress has been made in HIV/AIDS research over the past few decades, HIV infection
of humans remains a significant global issue. The use of NHP models of AIDS has
greatly enhanced our current knowledge of HIV pathogenesis, however, a comprehensive
understanding of the mechanisms underlying non-pathogenicity seen in SIV-infected
natural hosts is not completely understood.
Intriguingly, natural and non-natural hosts exhibit divergent responses to SIV
infection. When SM and RM are inoculated with unpassaged SIVsmm, infection results
in high viremia in both species. SIV-infected RM exhibited severe CD4 T cell depletion,
persistent generalized immune activation, chronic proliferation of lymphocytes, and
ultimately died from an AIDS-like disease, while SIV-infected SM displayed modest
lymphocyte proliferation and remained disease-free (25). This study clearly demonstrated
that the host dependent factors, rather than properties of the virus, play a central role in
immunodeficiency in SIV-infected RM, and highlights the importance of fully
investigating the underlying mechanisms responsible for non-pathogenicity in SIVinfected natural hosts. Many studies indicate key features of natural host SIV infection
that are associated with lack of disease progression. Such features include: preferential
sparing of critical cell subsets (i.e. central memory cells) from infection (1, 19), lack of
chronic immune activation (3, 10, 17), maintenance of mucosal immunity (8),
preservation of gut Th17 cells (4), and preservation of T cell homeostasis (18).
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For this dissertation, I identified a novel, non-functional SM-CCR5 mutant allele
(CCR5∆2), and determined the prevalence of this allele in a large SM colony.
Remarkably, animals homozygous for mutant CCR5 alleles were susceptible to SIV
infection in vivo, indicating that non-CCR5 pathways support SIV transmission and
replication in these CCR5-deficient animals. Moreover, this finding challenges the longstanding notion that CCR5 is the exclusive coreceptor used by SIV in vivo, and raises
many questions regarding the role alternative entry pathways play in SIV infection of
natural hosts.
In natural host SM, alternative coreceptor use in conjunction with restricted CCR5
expression may redirect infection to more expendable cell types, thus contributing to the
maintenance of immune cell homeostasis (Figure 4-1). While SIVmac utilizes
alternative coreceptors in vitro, CCR5 expression in RM is high and the role alternative
entry pathways play, in vivo, is less clear (Figure 4-2). In addition to implications for
SIV, alternative coreceptor expression and use may play a role in HIV infection of
humans since i) while rare, HIV alternative coreceptor use has been described, and ii)
with CCR5 knock-out efforts, acquisition of alternative coreceptor use by HIV may
become an issue.

Regulation of cellular receptors required for HIV/SIV entry and viral susceptibility
in CCR5-null hosts
SIV infection of multiple African NHP species is endemic and evidence suggests
that natural hosts have been infected with SIV since ancient times, which has likely led to
evolutionary adaptations in both virus and host. A potential host adaptation to SIV
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infection is the regulation of receptors and/or coreceptors required for SIV entry in a
manner that protects critical cells from infection. In AGM, selective downregulation of
CD4 was observed on primary lymphocytes transitioning from a naïve to memory
phenotype. Surprisingly, CD4-deficient memory cells maintained T cell functions, while
the loss of the surface-bound CD4 molecule protected these cells from SIVagm infection
in vivo (1).
Many natural host species (i.e. SM, AGM, sun-tailed monkeys and mandrills)
have developed mechanisms to differentially regulate CCR5 on specific cell subsets.
Natural hosts express extremely low levels of CCR5 on CD4+ T cells found in the
peripheral blood and in mucosal tissues, however CD8+ T cells from these hosts, express
considerably higher levels of CCR5 (21). Differential regulation of CCR5 expression is
also exhibited on SM CD4+ central memory T cells, which express significantly lower
levels of CCR5 than SM CD4+ effector memory T cells (19). Currently, the mechanisms
underlying CCR5 regulation remain unknown. However, this observation raises the
question, is low CCR5 expression on natural host CD4+ T cells an evolutionary
adaptation in direct response to SIV infection?
In contrast to intrinsic regulation of CCR5, CCR5 genetic polymorphisms that
abrogate surface expression have been identified in different host populations. In
humans, a 32 base-pair deletion in ECL2 has been described. Approximately, 1% of
Caucasians are homozygous for CCR5∆32 mutant alleles, and these individuals are
highly resistant to HIV infection. Notably, investigation of CCR5∆32 homozygous
individuals confirmed that CCR5 was the main coreceptor utilized by M-tropic strains of
HIV-1 and that these strains were critical for person-to-person transmission (16, 24).
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Another CCR5 mutant allele, CCR5∆24, was determined to be extremely
common in the RCM population, where ≥70% of these animals were homozygous for the
CCR5∆24 mutant allele (5). Despite a high prevalence of non-functional CCR5 alleles in
the RCM population, CCR5-null animals are not protected from SIV infection. SIVrcm
has adapted to use CCR2b as an entry coreceptor and lost the ability to use CCR5.
Notably, wild-type RCM-CCR5 is functional and supports entry for HIV-1, HIV-2 and
various strains of SIV (5).
In SM, I recently identified a novel CCR5 polymorphism, SM-CCR5∆2, and
determined a 26% allelic frequency for this mutant allele in a large SM colony housed at
the Yerkes primate center (23). I found that 8% of the SM housed at Yerkes were
homozygous for CCR5-defective alleles including CCR5∆2 and CCR5∆24 (20), which
had an allelic frequency of 3% in this colony. Surprisingly, 50% of the CCR5-null SM
were naturally infected with SIVsmm, thus the CCR5-null phenotype in SM does not
protect against SIV infection. In contrast to SIVrcm, SIVsmm Envs cloned from a
CCR5-null animal efficiently used CCR5 for entry as well as various alternative
coreceptors, but not CXCR4 or CCR2b (7, 23). Interestingly, SIVrcm and SIVsmm have
evolved to utilize different entry pathways in the absence of CCR5.
Remarkably, each of the three examples of populations with CCR5-null
individuals (SM, RCM and humans) demonstrates distinct patterns of host/virus
interactions. Intriguingly, CCR5-null humans (non-natural host) are protected from HIV
infection in vivo, whereas CCR5-null SM and RCM (natural hosts) remain susceptible to
SIV infection. The fact that natural hosts exhibit multiple mechanisms to reduce or
completely abrogate CCR5 expression suggests that low or restricted CCR5 levels may
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be advantageous to these hosts, possibly due to protecting critical cell subsets and a
reduction in the homing of CD4+ T cells to sites of inflammation. Additionally, it will be
interesting to explore if utilization of non-CCR5 entry pathways by SIV contribute to the
non-pathogenic nature of SIV in natural hosts.

Convergent evolution of CCR5 mutant alleles
Many polymorphisms in CCR5 have been identified and investigated (2, 14, 15),
and while a few mutant alleles were functionally defective, only three primate CCR5
deletion alleles have resulted in CCR5-null phenotypes to date: ∆32 in humans, ∆24 in
RCM/SM and ∆2 in SM. Identification of the SM-CCR5∆2 allele is the third example of
convergent evolution resulting in disruption of CCR5 expression and function in
primates.
Two questions regarding these mutant alleles remain unanswered: i) when did
they arise, and ii) what selective pressure(s) led to the retention of CCR5∆32, CCR5∆24
and CCR5∆2 in their respective species? It is estimated that the CCR5∆24 mutant allele
arose in an ancestral mangabey species over 10,000 years ago, prior to the formation of
natural barriers, which likely caused a subspecies divide forming the SM and RCM
populations (5). According to this estimation, the CCR5∆24 mutant allele has been
circulating in mangabey populations substantially longer than the CCR5∆32 mutant
allele, which is currently estimated to have entered the human population roughly 3,000
years ago (9, 11). Presently, it is unknown when the CCR5∆2 allele entered the SM
population; however, an estimate of the chronology of this mutation might be gained
from evaluating the closely related RCM. The presence of CCR5∆2 in the RCM
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population would suggest that, like CCR5∆24, CCR5∆2 was present roughly 10,000
years ago in an ancestral mangabey species prior to the sub-speciation of RCM and SM.
However, the absence of CCR5∆2 in the RCM population would suggest that the
CCR5∆2 mutant allele arose after the RCM/SM subspecies divide.
Currently, the selective event that led to the emergence of CCR5∆24 in the
RCM/SM population is unknown, however the emergence of CCR5∆32 in the human
population has been attributed to infectious pathogens. The high frequency of the
CCR5∆32 allele in Northern European populations has been ascribed to the bubonic
plague (“Black Death”) pandemic in the 14th century (26), however subsequent
predictions from a population genetic model suggest that the smallpox Variola major
virus is a more likely candidate for selection pressure leading to CCR5∆32 emergence
(9). Evidence clearly indicates that CCR5∆32 is not the result of selective pressure by
HIV since this virus recently entered the human population. However it is plausible that
endemic SIV infections in RCM and SM populations may have selected for the
emergence of CCR5∆24 and/or CCR5∆2 in these hosts.
Another question raised by our finding is whether the SM-CCR5∆2 and the
SM/RCM CCR5∆24 mutant alleles emerged independently resulting in deletions in the
same region of CCR5. Both the ∆2 and ∆24 deletions occurred in a region of TM4 where
multiple nucleotide repeats exist, which may have enabled recombination. However, this
potential recombination site (-GTGGTG-) is conserved in other primate species (humans,
chimpanzees and macaques) in which the ∆24 deletion (or any other deletion at this site)
was not observed (5). Extensive CCR5-genotyping of other mangabey subspecies may
identify deletions (∆2, ∆24 or others) in this particular region of CCR5. On one hand, if
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other deletions were observed, it would support the notion that CCR5∆2 and CCR5∆24
alleles arose independently in a region of CCR5 that has a high occurrence of
recombination, likely leading to nucleotide deletions. On the other hand, the CCR5∆2
and CCR5∆24 mutant alleles contain two identical point mutations (436T>G and
538C>T), which result in amino acids identical to those in human CCR5 at those
respective sites. If CCR5∆2 and CCR5∆24 arose from independent recombination
events, it is peculiar that the resulting mutant alleles would contain more than one
identical point mutation, in addition to deletions in the same region.

Alternative coreceptors: SIV use and viral tropism
It appears that natural hosts have developed multiple mechanisms to counter the
potential pathogenic effects of SIV such as attenuated chronic immune activation and
regulation of CCR5 expression through genetic polymorphisms or selective
downregulation on specific T cell subsets (19, 21). SIV use of alternative coreceptors in
vitro, has been extensively described over the past decade, however the potential
biological role of alternative coreceptor use by SIV in vivo has not been investigated.
Discovery of the SM-CCR5∆2 mutant allele has led to the identification of SIV-infected
CCR5-null SM emphasizing the biological relevance of non-CCR5 entry pathways in
these hosts. Additionally, SM-PBMC, either genetically deficient in CCR5 or treated
with a CCR5-specific inhibitor, supported SIV replication indicating non-CCR5 entry
pathways are available on SM primary cells (23). Furthermore, SM-derived alternative
coreceptors, CXCR6 and GPR15, efficiently supported entry by SIV Envs from CCR5expressing and CCR5-null SM, in vitro (7). Taken together, these findings indicate that
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alternative coreceptors play a major role in SIVsmm infection of CCR5-null SM, and
explain the widespread and efficient use of alternative coreceptors in vitro among the
SIVsmm/SIVmac family of viruses.
While alternative entry pathways solely support SIV transmission and replication
in CCR5-null hosts, it is unknown to what extent alternative coreceptors contribute to
SIV infection of CCR5-expressing SM. Remarkably, a modest yet significant difference
in viral loads was observed (~3-fold) between CCR5-expressing and CCR5-null animals,
with an intermediate gene dosage effect seen in the presence of one CCR5 allele. Based
on this finding, one could speculate that CCR5 and alternative pathways are expressed on
distinct or partially overlapping CD4+ T cell subsets, resulting in increased viral
replication in animals possessing both CCR5 and non-CCR5 entry pathways. One way to
address this question is by infecting SM-PBMC with replication-competent SIVsmm
containing a GFP reporter gene, and subsequently staining infected cells for CD4 and
coreceptors (CCR5, CXCR6 and GPR15). Analysis of coreceptor expression on SIV+
(GFP+) CD4 T cells will inform whether or not SIV infects cells expressing alternative
coreceptors, but not CCR5.
The recognition that both CCR5 and non-CCR5 pathways are used by SIV in SM
natural hosts has significant implications for understanding viral tropism in vivo. Since
CD4/coreceptor interactions determine viral tropism and cell targeting, the findings of
this thesis suggest that SIV infection in SM may involve target cells defined by the
distribution and use of alternative coreceptors CXCR6 and GPR15, in addition to CCR5.
Restricted expression of CCR5 on critical target cells (such as CD4+ central memory T
cells) in SM has been previously described and thought to contribute to immune cell
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homeostasis in these natural hosts (19). Combining the sparing of critical cell subsets
through restricted CCR5 expression and alternative coreceptor-dependent targeting may
allow virus replication in more expendable cells without the loss of immune cell
homeostasis. We hypothesize that SM natural hosts may have evolved to restrict
expression of CXCR6 and GPR15, in addition to CCR5, to dispensable cell subsets, thus
allowing for high viral replication without causing disease. An understanding of the
distribution of alternative coreceptors on primary SM cell subsets will elucidate SIVsmm
tropism in these hosts. Additionally, strains of SIV (SIVagm and SIVrcm) from other
natural hosts have been shown to use CXCR6 and/or GPR15 for entry in vitro (5, 6). It
will be interesting to explore whether entry through alternative coreceptors is a conserved
mechanism seen in multiple natural host species.
Another interesting question is do alternative coreceptors play a role in
pathogenic HIV/SIV infections? In line with the hypothesis that alternative coreceptor
use may contribute to non-pathogenicity seen in SIV-infected natural hosts, lack of
alternative coreceptor use in pathogenic infections could result from host and/or viral
parameters such as: i) species-specific polymorphisms that render non-natural host
alternative coreceptors non-functional for viral entry, ii) differences in alternative
coreceptor expression profiles between natural and non-natural hosts, which may affect
viral tropism, iii) evolutionary adaptations in the virus, which may prevent the use of
alternative coreceptors, and/or iv) high CCR5 expression in non-natural hosts that renders
use of alternative coreceptors superfluous. Along these lines, studies indicate that the
SIVmac virus family use CXCR6, GPR15 and a number of other alternative coreceptors
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in vitro, however there is evidence to suggest that SIVmac does not efficiently use RMderived CXCR6 (22).
In addition to implications for SIV, alternative coreceptor expression and use may
play a role in HIV infection of humans since therapeutic strategies aimed at knocking out
CCR5 genes, in an effort to engineer a CCR5-null phenotype, are currently underway.
Some concerns with this approach is that the absence of CCR5 expression may drive the
virus to utilize other coreceptors such as CXCR4, which is associated with accelerated
disease progression (13). In an attempt to circumvent this issue, both CCR5 and CXCR4
can be targeted for gene disruption, however a CCR5 and CXCR4-null immune
environment may further drive HIV to acquire the ability to use alternative coreceptors.
Although rare, HIV use of alternative coreceptors does occur in vivo. Recently, an HIV
transmitted/founder virus was identified that efficiently entered cells using GPR15, but
had impaired CCR5 and CXCR4 use (12). Based on my preliminary findings in chapter
3, CXCR6 and GPR15 are predominantly expressed on human CD4+ memory cells, thus
acquisition of alternative coreceptor use may result in infecting similar target cells as an
R5-tropic virus.
Taken together, these data suggest that SM natural hosts may have evolved to
restrict expression of CXCR6 and GPR15, in addition to CCR5, to dispensable cell
subsets, thus allowing for high viral replication without causing disease. Future studies
comparing CXCR6 and GPR15 expression profiles in natural and non-natural hosts will
be of importance in determining the role of alternative coreceptors in natural hosts in
vivo.
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Figure 4-1. Model of potential coreceptor expression patterns on CD4+ T cells of natural
hosts. Model demonstrating how restriction of CCR5 and alternative coreceptors (CXCR6 and
GPR15) to specific cell subsets may redirect viral tropism, thus sparing critical cell subsets
required for immune cell homeostasis, while targeting dispensable cell subsets allowing robust
replication. Restriction of coreceptor expression (CCR5, CXCR6 and GPR15) to specific cell
subsets may contribute to the non-pathogenic nature of SIV infection in natural hosts.
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Figure 4-2. Model of potential coreceptor expression patterns on CD4+ T cells of nonnatural hosts. Model demonstrating that non-natural hosts express moderate to high levels of
coreceptors on both critical and dispensable cell subsets. This type of expression likely promotes
equal infection in both critical and dispensable cell subsets, ultimately leading to loss of immune
cell homeostasis and immunodeficiency.

137

References
1.

2.

3.

4.

5.

6.
7.

8.

9.
10.

Beaumier, C. M., L. D. Harris, S. Goldstein, N. R. Klatt, S. Whitted, J.
McGinty, C. Apetrei, I. Pandrea, V. M. Hirsch, and J. M. Brenchley. 2009.
CD4 downregulation by memory CD4+ T cells in vivo renders African green
monkeys resistant to progressive SIVagm infection. Nat Med 15:879-85.
Blanpain, C., B. Lee, M. Tackoen, B. Puffer, A. Boom, F. Libert, M. Sharron,
V. Wittamer, G. Vassart, R. W. Doms, and M. Parmentier. 2000. Multiple
nonfunctional alleles of CCR5 are frequent in various human populations. Blood
96:1638-45.
Bosinger, S. E., Q. Li, S. N. Gordon, N. R. Klatt, L. Duan, L. Xu, N.
Francella, A. Sidahmed, A. J. Smith, E. M. Cramer, M. Zeng, D. Masopust,
J. V. Carlis, L. Ran, T. H. Vanderford, M. Paiardini, R. B. Isett, D. A.
Baldwin, J. G. Else, S. I. Staprans, G. Silvestri, A. T. Haase, and D. J. Kelvin.
2009. Global genomic analysis reveals rapid control of a robust innate response in
SIV-infected sooty mangabeys. J Clin Invest 119:3556-72.
Brenchley, J. M., M. Paiardini, K. S. Knox, A. I. Asher, B. Cervasi, T. E.
Asher, P. Scheinberg, D. A. Price, C. A. Hage, L. M. Kholi, A. Khoruts, I.
Frank, J. Else, T. Schacker, G. Silvestri, and D. C. Douek. 2008. Differential
Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.
Blood 112:2826-35.
Chen, Z., D. Kwon, Z. Jin, S. Monard, P. Telfer, M. S. Jones, C. Y. Lu, R. F.
Aguilar, D. D. Ho, and P. A. Marx. 1998. Natural infection of a homozygous
delta24 CCR5 red-capped mangabey with an R2b-tropic simian
immunodeficiency virus. J Exp Med 188:2057-65.
Deng, H. K., D. Unutmaz, V. N. KewalRamani, and D. R. Littman. 1997.
Expression cloning of new receptors used by simian and human
immunodeficiency viruses. Nature 388:296-300.
Elliott, S. T., N. E. Riddick, N. Francella, M. Paiardini, T. H. Vanderford, B.
Li, C. Apetrei, D. L. Sodora, C. A. Derdeyn, G. Silvestri, and R. G. Collman.
Cloning and analysis of sooty mangabey alternative coreceptors that support
simian immunodeficiency virus SIVsmm entry independently of CCR5. J Virol
86:898-908.
Estes, J. D., L. D. Harris, N. R. Klatt, B. Tabb, S. Pittaluga, M. Paiardini, G.
R. Barclay, J. Smedley, R. Pung, K. M. Oliveira, V. M. Hirsch, G. Silvestri,
D. C. Douek, C. J. Miller, A. T. Haase, J. Lifson, and J. M. Brenchley.
Damaged intestinal epithelial integrity linked to microbial translocation in
pathogenic simian immunodeficiency virus infections. PLoS Pathog 6:e1001052.
Galvani, A. P., and M. Slatkin. 2003. Evaluating plague and smallpox as
historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc
Natl Acad Sci U S A 100:15276-9.
Harris, L. D., B. Tabb, D. L. Sodora, M. Paiardini, N. R. Klatt, D. C. Douek,
G. Silvestri, M. Muller-Trutwin, I. Vasile-Pandrea, C. Apetrei, V. Hirsch, J.
Lifson, J. M. Brenchley, and J. D. Estes. Downregulation of robust acute type I
interferon responses distinguishes nonpathogenic simian immunodeficiency virus
138

11.
12.

13.

14.

15.

16.

17.
18.

19.

20.

(SIV) infection of natural hosts from pathogenic SIV infection of rhesus
macaques. J Virol 84:7886-91.
Hummel, S., D. Schmidt, B. Kremeyer, B. Herrmann, and M. Oppermann.
2005. Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age
skeletons. Genes Immun 6:371-4.
Jiang, C., N. F. Parrish, C. B. Wilen, H. Li, Y. Chen, J. W. Pavlicek, A. Berg,
X. Lu, H. Song, J. C. Tilton, J. M. Pfaff, E. A. Henning, J. M. Decker, M. A.
Moody, M. S. Drinker, R. Schutte, S. Freel, G. D. Tomaras, R. Nedellec, D. E.
Mosier, B. F. Haynes, G. M. Shaw, B. H. Hahn, R. W. Doms, and F. Gao.
Primary infection by a human immunodeficiency virus with atypical coreceptor
tropism. J Virol 85:10669-81.
Koot, M., I. P. M. Keet, A. H. V. Ros, R. E. Y. de Goede, M. T. L. Roos, R. A.
Coutinho, F. Miedema, P. T. A. Schellekens, and M. Tersmette. 1993.
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell
depletion and progression to AIDS. Ann.Intern.Med. 118:681-688.
Kuhmann, S. E., N. Madani, O. M. Diop, E. J. Platt, J. Morvan, M. C.
Muller-Trutwin, F. Barre-Sinoussi, and D. Kabat. 2001. Frequent substitution
polymorphisms in African green monkey CCR5 cluster at critical sites for
infections by simian immunodeficiency virus SIVagm, implying ancient virushost coevolution. J Virol 75:8449-60.
Kunstman, K. J., B. Puffer, B. T. Korber, C. Kuiken, U. R. Smith, J.
Kunstman, J. Stanton, M. Agy, R. Shibata, A. D. Yoder, S. Pillai, R. W.
Doms, P. Marx, and S. M. Wolinsky. 2003. Structure and function of CCchemokine receptor 5 homologues derived from representative primate species
and subspecies of the taxonomic suborders Prosimii and Anthropoidea. J Virol
77:12310-8.
Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E.
MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996.
Homozygous defect in HIV-1 coreceptor accounts for resistance of some
multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
Manches, O., and N. Bhardwaj. 2009. Resolution of immune activation defines
nonpathogenic SIV infection. J Clin Invest 119:3512-5.
Paiardini, M., B. Cervasi, J. C. Engram, S. N. Gordon, N. R. Klatt, A.
Muthukumar, J. Else, R. S. Mittler, S. I. Staprans, D. L. Sodora, and G.
Silvestri. 2009. Bone marrow-based homeostatic proliferation of mature T cells in
nonhuman primates: implications for AIDS pathogenesis. Blood 113:612-21.
Paiardini, M., B. Cervasi, E. Reyes-Aviles, L. Micci, A. M. Ortiz, A.
Chahroudi, C. Vinton, S. N. Gordon, S. E. Bosinger, N. Francella, P. L.
Hallberg, E. Cramer, T. Schlub, M. L. Chan, N. E. Riddick, R. G. Collman,
C. Apetrei, I. Pandrea, J. Else, J. Munch, F. Kirchhoff, M. P. Davenport, J.
M. Brenchley, and G. Silvestri. Low levels of SIV infection in sooty mangabey
central memory CD T cells are associated with limited CCR5 expression. Nat
Med 17:830-6.
Palacios, E., L. Digilio, H. M. McClure, Z. Chen, P. A. Marx, M. A.
Goldsmith, and R. M. Grant. 1998. Parallel evolution of CCR5-null phenotypes
139

21.

22.

23.

24.

25.

26.

in humans and in a natural host of simian immunodeficiency virus. Curr Biol
8:943-6.
Pandrea, I., C. Apetrei, S. Gordon, J. Barbercheck, J. Dufour, R. Bohm, B.
Sumpter, P. Roques, P. A. Marx, V. M. Hirsch, A. Kaur, A. A. Lackner, R. S.
Veazey, and G. Silvestri. 2007. Paucity of CD4+CCR5+ T cells is a typical
feature of natural SIV hosts. Blood 109:1069-76.
Pohlmann, S., B. Lee, S. Meister, M. Krumbiegel, G. Leslie, R. W. Doms, and
F. Kirchhoff. 2000. Simian immunodeficiency virus utilizes human and sooty
mangabey but not rhesus macaque STRL33 for efficient entry. J Virol 74:507582.
Riddick, N. E., E. A. Hermann, L. M. Loftin, S. T. Elliott, W. C. Wey, B.
Cervasi, J. Taaffe, J. C. Engram, B. Li, J. G. Else, Y. Li, B. H. Hahn, C. A.
Derdeyn, D. L. Sodora, C. Apetrei, M. Paiardini, G. Silvestri, and R. G.
Collman. A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm
infection of CCR5-null natural hosts and efficient alternative coreceptor use in
vivo. PLoS Pathog 6:e1001064.
Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S.
Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C.
Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth,
R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier. 1996. Resistance
to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5
chemokine receptor gene. Nature 382:722-5.
Silvestri, G., A. Fedanov, S. Germon, N. Kozyr, W. J. Kaiser, D. A. Garber,
H. McClure, M. B. Feinberg, and S. I. Staprans. 2005. Divergent host
responses during primary simian immunodeficiency virus SIVsm infection of
natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol 79:404354.
Stephens, J. C., D. E. Reich, D. B. Goldstein, H. D. Shin, M. W. Smith, M.
Carrington, C. Winkler, G. A. Huttley, R. Allikmets, L. Schriml, B. Gerrard,
M. Malasky, M. D. Ramos, S. Morlot, M. Tzetis, C. Oddoux, F. S. di Giovine,
G. Nasioulas, D. Chandler, M. Aseev, M. Hanson, L. Kalaydjieva, D. Glavac,
P. Gasparini, E. Kanavakis, M. Claustres, M. Kambouris, H. Ostrer, G. Duff,
V. Baranov, H. Sibul, A. Metspalu, D. Goldman, N. Martin, D. Duffy, J.
Schmidtke, X. Estivill, S. J. O'Brien, and M. Dean. 1998. Dating the origin of
the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J
Hum Genet 62:1507-15.

140

